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SUMMARY 
Cystic fibrosis (CF) is the most frequent severe autosomal recessive disorder in the European 
population. The gene is located on the long arm of chromosome 7 and encodes for CFTR protein 
(Cystic Fibrosis Transmembrane Conductance Regulator). Despite the disease involves different 
organs, the most clinically relevant symptoms are found in the lung. Recently, given the monogenic 
nature of CF, different gene therapy strategies have been developed, but the results show that the 
correction of the defect is only temporary. Therefore, a novel approach based on stem cell-based 
therapy for reconstitution of the airway epithelium and CFTR expression should be explored.  
CF is a potential model disease for stem cell therapy because of the persistent lung inflammation 
that leads to damage and remodeling, and can promote engraftment of stem cells. If stem cells, 
transferred through autologous or heterologous transplant, would harbour in stem niches of 
respiratory epithelium, then the restoration of genetic and cellular damage will be definitive.  
In the last years, several cell populations derived from adult bone marrow, amniotic fluid or  
umbilical cord blood, have been shown to differentiate in different epithelia, including respiratory. 
Even if the in vivo efficiency of bone marrow stem cells to differentiate in airway epithelium is very 
low, recent studies demonstrate that a small percentage of corrected cells is needed to revert the 
defect. Bone marrow mesenchymal stem cells are not without drawbacks, e.g. they are limited in 
numbers and lack well-defined markers required for their purification. One approach to overcome 
these limitations is to consider alternative sources of stem cells capable of repopulating damaged 
respiratory epithelium.  
In the present study, we evaluated the possibility of obtaining stem cells from an ethically 
acceptable source as human placenta. 
As a potential source of cells for application in CF therapy, the placenta has the advantage of being 
a natural by-product of birth which is often simply discarded, while harvest of term amniotic 
membrane does not pose any risk to the mother or newborn.  
We demonstrated that amniotic membrane is a fetal tissue rich in cells with stem cell characteristics 
and with the capacity to remain “plastic” in their differentiation options. Furthermore, amniotic 
cells display features as low immunogenicity and non tumorigenicity. 
For the first time, our results provided evidence that human amniotic epithelial cells (hAECs) and 
amniotic mesenchimal stromal cells (hAMSCs) can be induced in vitro to express markers of 
airway epithelial phenotype, like CFTR and ZO-1, particularly when co-cultivated with CF human 
epithelial bronchial cells, and so have the potential to differentiate into airway epithelial cells.  
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Overall, our data showed that these cells may contribute to partial correction of the CF phenotype 
and are very likely an ideal candidate for cell-based therapy for CF. 
Whether the beneficial effects of placenta-derived cells are due to differentiation of the transplanted 
cells themselves or to paracrine actions on the surrounding host tissue in order to reduce 
inflammation and promote regeneration remains to be fully elucidated. In any case, the promising 
data obtained to date constitute compelling evidence regarding the potential utility of these cells for 
clinical application.  
Future studies testing these cells in in vivo model, will help in finding a strategy of cell therapy for 
the cure of respiratory disease of CF, directly transferable to CF patients. 
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RIASSUNTO 
La fibrosi cistica (FC) è la più frequente malattia autosomica recessiva letale nella razza caucasica. 
Il gene responsabile è localizzato sul braccio lungo del cromosoma 7 e codifica per una proteina 
denominata CFTR (Cystic Fibrosis Transmembrane Conductance Regulator). Nonostante la 
patologia interessi diversi organi, i sintomi clinicamente più rilevanti si riscontrano a livello 
polmonare. Data la natura monogenica della FC, negli ultimi anni si stanno sviluppando diverse 
strategie di terapia genica; tuttavia poiché dai risultati finora disponibili la correzione del difetto di 
base sembra essere solo temporanea, si cerca di indagare nuovi approcci basati su cellule staminali 
che possano ricostituire l‟epitelio danneggiato ed esprimere una proteina CFTR “wild-type”. Se le 
cellule staminali, trasferite attraverso trapianto autologo o eterologo, localizzassero nelle “stem 
niches” dell‟epitelio respiratorio, la riparazione del danno genetico e cellulare sarebbe definitivo. 
Negli ultimi anni, diverse popolazioni cellulari (cellule staminali adulte da midollo osseo, liquido 
amniotico o sangue del cordone ombelicale) hanno mostrato la capacità di differenziare in diversi 
epiteli, tra cui il respiratorio. 
Anche se l‟efficienza delle cellule staminali da midollo osseo di differenziare in vivo in epitelio 
respiratorio è molto bassa, studi recenti hanno dimostrato che è necessaria una piccola percentuale 
di cellule per correggere il difetto. Vi sono però limiti circa l‟utilizzo delle staminali da midollo 
osseo, come lo scarso numero e la mancanza di marcatori specifici per la loro purificazione. Un 
approccio valido per superare tali limiti è quello di considerare fonti alternative di cellule staminali 
capaci di ripopolare l‟epitelio respiratorio danneggiato.  
Questo studio intende valutare la possibilità di utilizzare cellule staminali pluripotenti ottenute dalla 
membrana amniotica della placenta, per la messa a punto di una terapia cellulare per la cura della 
FC. 
La placenta ha il vantaggio di essere un tessuto generalmente eliminato dopo il parto il cui prelievo 
non comporta alcun rischio per la salute della madre o del neonato. 
Abbiamo dimostrato che la membrane amniotica è un tessuto fetale ricco in cellule che possiedono 
caratteristiche tipiche delle cellule staminali e che hanno capacità di differenziare verso cellule dei 
diversi foglietti embrionali. Inoltre, le cellule della membrana amniotica mostrano proprietà 
immunomodulatorie e sembrano non indurre tumori negli animali trapiantati. 
I nostri risultati hanno documentato per la prima volta che le cellule epiteliali amniotiche (hAECs) e 
mesenchimali stromali amniotiche (hAMSCs) possono essere indotte in vitro ad esprimere 
marcatori di epitelio respiratorio, come CFTR e ZO-1, in modo particolare quando sono co-coltivate 
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con cellule di epitelio bronchiale FC, dimostrando così la potenzialità di queste cellule di 
differenziare in cellule dell‟epitelio respiratorio. 
In conclusione, i nostri dati provano che queste cellule possono contribuire parzialmente alla 
correzione del fenotipo FC e quindi possono rappresentare un candidato ideale alla terapia cellulare 
per questa patologia. 
Rimane da chiarire se gli effetti benefici delle cellule della membrana amniotica siano dovuti a 
differenziamento delle cellule stesse o ad effetti paracrini sul tessuto circostante, volti a ridurre 
l‟infiammazione e a promuovere la rigenerazione. In ogni caso, i dati promettenti ottenuti fino ad 
oggi costituiscono una prova convincente della potenziale utilità di queste cellule per l‟applicazione 
clinica. 
Studi futuri volti a testare queste cellule in un modello in vivo sono necessari al fine di trovare una 
strategia di terapia cellulare per la cura della malattia respiratoria di FC, direttamente trasferibile ai 
pazienti. 
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1. INTRODUCTION 
Basic and clinical research accomplished during the last few years on stem cells has constituted a 
revolution in regenerative medicine by generating multiple possible therapeutically useful cell 
types. Intense research on stem cells has provided important information on developmental, 
morphological and physiological processes that govern tissue and organ formation, maintenance, 
regeneration and repair after injury. More recently, significant advances in the understanding of 
stem cell biology have provoked great interest and hold high therapeutic promises based on the 
possibility of stimulating the ex vivo and in vivo expansion and differentiation into functional 
progeny that could regenerate the injured tissue/organ firstly in animals and then in humans 
(Mimeault M et al, 2007) 
 
1.1 Cystic fibrosis 
Cystic fibrosis (CF) is the most common fatal genetic disorder in Caucasians, with an incidence of 1 
in 2,500-2,700 live births (Ratjen and Doring, 2003).  
Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator 
(CFTR) gene, which encodes a chloride channel that is expressed on the apical membrane of 
secretory epithelia. The absence of functional CFTR in airway epithelia of patients with CF leads to 
abnormal airway surface liquid, which favors chronic infection with Pseudomonas aeruginosa 
(PA), Staphylococcus aureus, Burkholderia cepacia and other bacteria. This chronic infection in CF 
lungs is associated with an exaggerated inflammatory response leading to pulmonary disease, the 
first cause of death in CF. 
Exocrine pancreatic insufficiency is present in about 90% of patients with cystic fibrosis. Pancreatic 
disease is thought to result from a reduced volume of pancreatic secretion with low concentrations 
of HCO3
–
 (Kopelman et al, 1985) Without sufficient fluid and HCO3
–
, digestive proenzymes are 
retained in pancreatic ducts and prematurely activated, ultimately leading to tissue destruction and 
fibrosis. The resulting malabsorption contributes to the failure to meet raised energy demands 
caused by the hypermetabolic state associated with endobronchial infection. 
Ninety-eight percent of men with cystic fibrosis are infertile, with aspermia secondary to atretic or 
absent vasa deferentia and dilated or absent seminal vesicles (Dodge, 1995). Female reproductive 
function is normal, although cervical mucus can be dehydrated, which might impair fertility (Kopito 
et al, 1973). 
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Life expectancy has increased dramatically in people with CF over the past several decades due to 
availability of intravenous antibiotics, pancreatic enzymes and nutritional support, improved 
standards of care, newborn screening and development of new therapies. 
Indeed, many exciting discoveries have been made in the two decades since the gene responsible for 
CF was described. New therapies and approaches to treatment have also been developed, some of 
which may have applications in other types of genetic diseases.  
 
1.1.1  Pathophysiology 
CF is an autosomal recessive disorder caused by mutations in the cystic fibrosis transmembrane 
conductance regulator (CFTR) gene located on the long arm of chromosome 7 (Lommatzsch and 
Aris, 2009; Rowe et al. 2005). The CFTR gene encodes for the CFTR protein which is a chloride 
channel present in the epithelial cells of many organs and an important contributor to salt and water 
balance (Figure 1).  
Approximately 4% of all Caucasians carry a 
single CFTR mutation and do not usually 
show any phenotypic abnormalities. 
However, when two mutations are present, 
CFTR protein does not function properly as 
a chloride channel with manifestations 
developing in multiple organs, such as 
lungs, pancreas, gastrointestinal tract, liver, 
sweat glands and reproductive tract. After 
description of the CF gene in 1989 
(Riordan et al, 1989), it soon became clear 
that CF genetics was more complex than 
originally thought and there are now more 
than 1600 described mutations 
(www.genet.sickkids.on.ca). The most 
common mutation worldwide is deletion of phenylalanine in the 508 position (F508del) found in 
almost 70% of patients. This causes a misfolding of CFTR protein leading to degradation within the 
cell. CFTR mutations are grouped into six classes, depending on the alterations of CFTR production 
and function within the cell (Figure 2a). CFTR may not be synthesized (class I), have inadequate 
processing (class II), lack regulation (class III), have reduced conductance (class IV), have partially 
Figure 1- Scheme of the structure of CFTR 
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defective production (class V) or accelerated turnover (class VI). F508del is a class II mutation and, 
in general, class I, II and III mutations are more likely to be associated with pancreatic insufficiency 
and more severe disease manifestations. When CFTR is absent or has decreased function in the 
apical membrane of the airway epithelium, the abnormalities in chloride and water flux are thought 
to cause a decrease in the airway surface liquid (Ratjen, 2009). This, in turn, leads to thick 
hyperviscous mucus, disruption in mucociliary clearance and a vicious cycle of neutrophil-
dominant inflammation and bacterial colonization and chronic infection. Ongoing chronic infection 
and inflammation leads to tissue destruction and bronchiectasis with airway obstruction, a process 
that eventually ends with respiratory failure (Figure 2b).  
 
 
Figure 2 – Mechanism of CF dysfunction. (a) Classes of CF mutation that facilitate correction of the basic defect 
through a ‟mutation-specific‟ approach (Box 1). (b) The CF pathogenesis cascade in the lung, from the primary CFTR 
gene defect to lung deficiency (Amaral and Kunzelmann, 2007). 
 
The clinical course of CF lung disease is usually one of episodic exacerbations of pulmonary 
infection and inflammation interspersed with periods of relative stability. Airway microbiology may 
change over the lifetime of a person with CF, with Staphylococcus aureus and Haemophilus 
influenzae being the most common organisms isolated in infancy and childhood and Pseudomonas 
aeruginosa more likely to be cultured from adults. Treatment strategies may vary from center to 
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center, but common approaches include the use of aggressive airway clearance, inhaled mucolytics 
and airway rehydrators, antiinflammatory agents, and inhaled and intravenous antibiotics. While 
new therapies have become available to address evacuation of airway mucus and treat airway 
inflammation and infection, there are currently many more novel therapies in various stages of 
clinical development, targeted at all points of the disease cascade from CFTR abnormalities to 
chronic infection (Ashlock et al, 2009).  
 
1.1.2 The respiratory system and the airway epithelium 
The respiratory tract consists of upper and lower airways. The nose, followed by the sinuses, mouth, 
and the throat, make up the upper airways, while the trachea, bronchi, and lungs and their internal 
structures are contained in the lower airways. The bronchi branch into smaller bronchi and then the 
bronchioles, ending with air sacs called the alveoli where gas exchange takes place. These are all 
contained inside lobes of the lungs. The entire respiratory 
system is lined with epithelial cells containing a number of 
different cell types with specific structure and function. An 
anatomical overview of the airways is shown in Fig. 3.  
 
 
The respiratory tree is lined with several specialized epithelial cell types that fulfill a number of 
functions to ensure lung homeostasis. There are at least 8 morphologically unique epithelial cell 
types, which can be classified into three categories: basal, ciliated columnar and non-ciliated 
secretory columnar cells (Knight and Holgate, 2003) depending on the region in which they are 
found in the respiratory system. Immune and inflammatory cells are also seen to migrate to and 
remain in the airway epithelium through the basement membrane to aid in epithelial cell function. 
Basal cells are strongly attached to the basement membrane via specialized cell-extracellular matrix 
(ECM) junctions, termed hemidesmosomes, which confer additional mechanical integrity in the 
tissue (Green and Jones, 1996). Similarly, basal-columnar interactions are ensured via the  
intercellular adhesion molecules that belong to cadherin family (desmosomes), which also create 
trans-cellular networks throughout the tissue giving it the ability to resist mechanical stress (Green 
Figure 3. Anatomical overview of the lung and the putative stem/ 
progenitor cell niches in the (mouse) lung: (a) a ductal cell in the 
submucosal gland, (b) basal cells in the intercartilaginous zones of the 
lower trachea, (c) Clara cells in the bronchioles, (d) Clara cells at the 
bronchiolar-alveolar duct junctions, and (e) alveolar type II cells. Note 
that the mouse only has submucosal glands in the proximal trachea, in 
contrast to the human (Roomans, 2010). 
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and Jones, 1996). As for columnar-columnar interactions, these depend upon belt like tight 
junctions (zona occludens), responsible for cellular transport regulation, and adherence is also 
maintained via E-cadherin adherens junctions (Roche et al, 1993). 
The wall of the trachea and bronchi in the normal human airway consists of a surface epithelium 
(with ciliated, brush, basal, and secretory cells), approximately 50 μm thick, resting on a basement 
membrane. Then follow layers 
of connective tissue and 
smooth muscle (not clearly 
separated), and finally,  
cartilage (Fig. 4).  
The bronchioli lack cartilage. 
The epithelium in the major 
bronchi and proximal 
bronchioles (Fig. 5a) is a 
ciliated pseudostratified 
epithelium, with ciliated 
columnar cells as the 
predominant cell type; in the 
distal bronchioles the epithelium consists of a single cell layer (Fig. 5b). The ciliated columnar cells 
reach the basal lamina with slender basal processes (Shebani et al, 2005). The function of the brush 
cells of the airway epithelium is not completely known. These cells lack cilia, and may be involved 
in detoxification, act as a sensor for airway surface liquid, or may have a chemoreceptor function. 
The pyramid-shaped basal cells rest on the basal lamina but do not reach the airway lumen. The 
average half-life of the ciliated cells has recently been reported to be 6 months in the trachea and 17 
months in the lung, which is much longer than previously estimated (Rawlins and Hogan, 2008). 
This makes the airway epithelium a tissue with a slow turn-over, which is relevant for its repair 
(Snyder et al, 2009). Different kinds of secretory cells (goblet cells in the trachea, bronchi and 
proximal bronchioles, Clara cells in the bronchioles, and neuroendocrine cells in the intrapulmonary 
airways) comprise around 20% of the bronchial and nasal epithelium and produce airway secretion 
(fluid and mucus). In addition, the Clara cell secretes Clara cell secretory protein (CCSP), an 
immunoregulatory protein (Snyder et al, 2009). The wall of the alveoli consists of squamous 
alveolar type I and surfactant-producing alveolar type II cells (Fig. 5c).  
Figure 4 - Overview of the airway wall (Roomans, 2010). 
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1.1.2.1 Basal cells 
Basal cells are abundant in the conducting 
airways although their number decreases 
according to the size of the region (Wang et al, 
1992). They have pyramidal shape with low 
cytoplasm to nucleus ratio (Evans et al, 2001). 
Historically, basal cells were thought to be the 
origin of stem cells in the airway epithelium, 
giving rise to ciliated and secretory columnar 
cells in larger airways (Boers et al, 1998). In 
addition to their possible progenitor role and 
attachment of superficial cells to the basement 
membrane, basal cells also secret a number of 
active molecules including cytokines, 
chemokines, and growth factors.  
 
 
1.1.2.2 Columnar secretory cells 
These cells are present at the apical surface of the epithelial layer. In large airways, mucus-secreting 
goblet cells are the predominant secretory cells and the main source of airway mucus. They are  
characterized by membrane-bound electron-lucent acidic mucin granules (Jeffery and Li, 1997). 
Mucus is secreted to trap any toxin and foreign molecules that the airway epithelium comes into 
contact with and thus these are the epithelial cell type involved in the mucociliary clearance 
function of the airway epithelium. These mucus goblet cells are seen in larger airways (trachea and 
bronchi), while Clara cells are found in smaller airways (terminal bronchioles). Mucous and Clara 
cells also contain electron dense granules (Jeffery and Li, 1997). Clara cells are believed to 
metabolize xenobiotic compounds by the action of p450 mono-oxygenases, and they produce 
bronchiolar surfactant (Joan Gil, 1971) as well as having ion absorbing and secreting  properties 
(Van Scott et al, 1987). Moreover, Clara cell populations are thought to contain the stem or 
progenitor cells of the small airway epithelium where mucus goblet cells and basal cells are sparse 
(Hong et al, 2001). Another type of secretory cell is the serous cell, resembling mucus goblet cells 
with a difference in granule content where it is seen to be electron-dense. These cells have only 
a)
c)
b)
Figure 5 - (a) The bronchial epithelium, with ciliated and 
goblet cells, (b) the bronchiolar epithelium and (c) the 
alveoli (Roomans, 2010). 
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been found in rodent airways, but two populations of these rare cells have been observed in small 
airways of human lung (Rogers et al, 1993). 
 
1.1.2.3 Columnar ciliated cells 
Ciliated cells account for over 50% of all epithelial cells within the airways (Knight and Holgate, 
2003). It is thought that these cells arise from secretory or basal cells and were initially thought to 
be terminally differentiated. Their primary role is the directional transport of mucus, or any foreign 
object, from the lung to the throat.  
 
1.1.2.4 Alveolar type I cells 
Covering 90-95% of the alveolar surface, alveolar type I cells are one of the two types of alveolar 
epithelial cells (Crapo et al, 1982). They are squamous thin cells that are very susceptible to injury. 
Alveolar type I cells are unable to divide, and form a thin blood-gas barrier where gas exchange 
occurs. They are important in maintaining the normal cellular composition and function of the 
alveolar epithelium (Williams, 2003). It has been clear that alveolar type I cells are involved in 
maintaining homeostasis in the alveolar epithelium (Berthiaume et al, 2006).  
 
1.1.2.5 Alveolar type II cells 
Type II cells are cuboidal in shape covering 5% of the distal lung. They serve as stem or progenitor 
cells for type I cells after alveolar injury and play a major role in gas exchange (Sugahara et al, 
2006). One other major function of type II cells is their surfactant protein (SP) production 
(especially SPC), and phospholipids production which line the alveoli differentially reducing 
surface tension at different volumes contributing to alveolar stability (Witherden et al, 2004; 
Mason, 2006). 
 
1.1.2.6 Pulmonary neuroendocrine cells (PNEC)  
In addition to the above main epithelial cell types, pulmonary neuroendocrine cells (PNEC) are 
present throughout the bronchial tree either clustered in neuroepithelial bodies (NEB) or as 
individual cells (Gosney et al, 1988). These cells are thought to be very rare, increasing in number 
in chronic bronchitis. PNEC are thought to be involved in the secretion of a number of amines and 
peptides vital for foetal lung growth and airway function (Reynolds et al, 2000) and may play role 
in localized epithelial cell regeneration. 
 
INTRODUCTION: Cystic Fibrosis 
 
 
 
9 
1.1.2.7 Other cell types surrounding the airway epithelium 
The airway epithelium is underlined by (myo) fibroblasts, smooth muscle cells, blood vessels, 
afferent nerve endings, and immune cells. Fibroblasts are present beneath the basement membrane 
where the epithelium rests. They play a role in tissue repair and airway remodelling by secreting 
growth and attachment factors (Pollak et al, 1992) and chemotactic cytokines stimulating the 
bronchial epithelium to migrate following injury and thus contributing to the repair mechanism 
(Shoji et al, 1989). Surrounding the airway wall are airway smooth muscle cells (ASMC) from the 
trachea down to the alveolar duct controlling contraction and relaxation of the airway walls. These 
responses are regulated by intracellular signalling pathways (Hall, 2000) achieved via a series of 
homeostatic mechanisms though phospholipase C, adenyl cyclase, and ion channel pathways.  
 
1.1.2.8 Basement membrane (BM) 
Basement membrane (BM), also called the basal lamina, is a thin sheet-like membrane (40-120 nm 
thick), upon which basal epithelial cells adhere, consisting of ECM proteins, anchoring filaments of 
laminin 5, collagen IV, and proteoglycans including perlecan (Altraja et al, 1996). BM consists of a 
lamina lucida and a lower lamina densa. Below the BM, the reticular basement membrane – a layer 
of collagenous matrix – is found where fibroblasts are embedded. Collagen, proteoglycans, and 
glycoproteins, are present in all layers of the BM in differing combinations. BM plays a role in 
holding all the epithelial cells together and also in epithelial-mesenchymal interactions. In addition 
to its structural support role, BM facilitates adhesion and migration of epithelial cells through ECM 
protein interactions and acts as a reservoir for growth factors. It is also required for the 
establishment of correct epithelial polarity (Howat et al, 2001). Recently, pores which traverse the 
whole BM thickness have been observed, wide enough to allow the cells from the lamina propria to 
cross into the epithelium without matrix degradation (Howat et al, 2001). 
 
1.1.2.9 Embryonic development of the lung 
In the human, the embryonic lung starts to develop during the fourth week of embryonic 
development, when a ventral protuberance in the foregut is formed, the respiratory diverticulum 
(Fig. 6a) (Larsen, 1993). This entodermal protuberance is covered by mesodermal splanchnopleure, 
which will develop first into the connective tissue lamina propria, and then into the smooth muscle 
and cartilage of the airway wall, whereas the blood vessels develop from the aortic arch. On day 26-
28, the protuberance splits into two primary bronchial protuberances (the origin of the two lungs), 
and during the fifth week secondary bronchial protuberances (three on the right side and two on the 
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left side: the lung lobes, Fig. 6b) are formed. During the sixth week the tertiary bronchial 
protuberances are formed that will give rise to the lung segments (Fig. 6c). The protuberances 
continue to divide during weeks 26-28; the 16th division forms the terminal bronchioles that 
subsequently give off the respiratory bronchioles and alveolar saccules (week 26) (Fig. 6d). From 
about week 32, primitive alveoli are formed. Between week 36 and birth, the alveoli (Fig. 6e) 
mature and from parturition on until the age of 8-10 years, new respiratory bronchioles and alveoli 
are formed. Only at this age the lungs are fully developed (although the lungs retain regenerative 
capacity at an advanced age, e.g., after surgical resection). 
 
(a) (b) (c) (d) (e) 
 
Figure 6 - Embryonic development of the lungs. (a) Formation of an entodermal diverticulum (respiratory 
diverticulum) (from the foregut) and the two anlage for the right and left lung, (b) the lung lobes with primary and lobar 
bronchi, (c) the segmental bronchi; behind the lung are the oesophagus and the stomach, (d) the bronchial tree and the 
formation of alveolar saccules, (e) the alveoli (development of the alveoli continues after birth until about 8 years of 
age) (Roomans, 2010). 
 
 
Organ morphogenesis is, in general, controlled by cell-cell signaling between the epithelium, the 
mesenchyme, and the vasculature. In practice, therefore, repair of a defect in the airway wall will 
require, at a minimum, progenitors of epithelial cells, basement membrane, and fibroblasts, as well 
as cells able to form blood vessels. Damage to the airway epithelium may be the result of a number 
of airway diseases. In addition, extraneous chemicals, e.g., air pollution from traffic or industrial 
activities, may cause damage to the epithelium. However, even under normal conditions, there has 
to be a turn-over of the cells of the airway wall. Tissues with a relatively slow turn-over, use the 
self-renewal of differentiated cells as a strategy for tissue regeneration (Rawlins and Hogan, 2006). 
In addition, damage to the airway epithelium occurs frequently, e.g., due to components of smoke, 
air pollution, or to bacterial and viral infection, either from direct effects of these microorganisms or 
due to the inflammatory reaction that follows infection. Normally, in the case of small lesions, the 
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airway epithelium possesses repair mechanisms that can restore the normal structure. If the damage 
is more extensive, the repair process is more extensive, and is called airway remodeling (Folli et al, 
2008). Airway repair appears to be controlled both by bronchial epithelial cells and by endothelial 
cells of the perfusing bronchial vasculature (Zani et al, 2008). 
 
1.1.3 Target cells for gene transfer 
Because the pulmonary disease in CF, which is characterized by abnormal mucus secretion, chronic 
bacterial infection, and airway inflammation, is the major cause of morbidity and mortality, the lung 
was the first target organ for gene replacement. To have successful CFTR gene transfer, the biology 
of CFTR and its function and the necessary target cell(s) for gene therapy need to be understood. At 
the cellular level, CFTR is an apical membrane protein found in several types of lung epithelial 
cells that serves as a regulated chloride channel (Rich et al, 1990). Through interactions between 
CFTR and the amiloride-sensitive epithelial sodium channel (ENaC), absence of functional CFTR 
in CF epithelial cells results in sodium hyperabsorption and lack of cyclic adenosine 
monophosphate–mediated chloride secretion (Boucher, 1994). CFTR is important for other cellular 
functions, including post-translational processing of high-molecular-weight glycoconjugates and 
cell surface receptors, pH regulation of intracellular organelles and airway surface liquid, regulation 
of membrane trafficking, secretion of mucus, and regulation of glutathione transport (Metha, 2005). 
There are increasing data demonstrating that constitutive and stimulated release of soluble 
inflammatory mediators is increased from CF airway epithelial cells. This may reflect, in part, 
increased basal and stimulated cell signaling resulting from increased nuclear factor–kB activity, 
AMP-dependent kinase activity, or altered antioxidant homeostasis in cells with defective CFTR 
(Machen, 2006). Although the mechanisms for many of these effects remain incompletely 
understood, they provide evidence of the complexity and multiple cellular effects that need to be 
considered with CFTR gene replacement. At the organ level, CFTR in lung is localized primarily at 
the ciliated cells of the proximal airways and the ciliated cells of the submucosal glands, which are 
located primarily in the proximal airways. Whether CFTR is substantially expressed in other 
epithelial cell types remains unclear. Earlier studies suggesting expression in non-ciliated airway 
epithelial cells of the airways and glands, including basal epithelial cells, have been contradicted by 
more recent studies demonstrating that, although CFTR mRNA may be found in these cells, levels 
of CFTR protein expression are low and of uncertain significance (Anson et al, 2006; Kreda et al, 
2005). Moreover, although CFTR can be detected in type 2 alveolar epithelial cells, CFTR 
expression is generally highest in proximal as compared with distal airways and alveoli (Anson et 
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al, 2006). This suggests that targeting the ciliated cells, primarily in the submucosal glands, will 
have most effect on regulation of mucus and airway surface liquid and presumably ameliorate the 
most relevant pathophysiologic respiratory effects of defective CFTR. However, there is turnover of 
the differentiated ciliated epithelial cells, and targeting the underlying basal progenitor epithelial 
cells may be a more viable approach to provide for longer- lasting or even indefinite expression. 
Progress has been made toward identifying endogenous progenitor cells resident in proximal and 
distal airways, but no viable strategy for specifically targeting these cells with gene transfer vectors 
has been identified. Targeting defective CFTR alone may not fully correct airway disease. This is 
exemplified by the development of the ENaC over-expressing mouse (Mall et al, 2004). Unlike the 
CFTR knockout or F508del transgenic mice, which do not develop substantial airway disease, 
increased airway sodium absorption in the airways of the ENaC mice resulted in airway surface 
liquid volume depletion, increased mucus concentration, delayed mucus transport, and mucus 
adhesion to airway surfaces (Mall et al, 2004). The mice also developed severe spontaneous lung 
disease, comparable to that in patients who have CF, including mucus obstruction, goblet cell 
metaplasia, neutrophilic inflammation, and poor bacterial clearance. This provides evidence of the 
important role of ENaC in the development of many of the clinical manifestations of CF lung 
disease. Whether replacing defective CFTR results in appropriate regulation of ENaC remains 
unclear. Further, because none of the vectors used or currently being used in human trials efficiently 
achieves gene transfer to submucosal glands, if normal CFTR and thus normal ENaC function in 
submucosal glands are necessary for normal airway clearance, current approaches are not likely to 
affect disease pathogenesis in the proximal airways. However, efficient gene transfer to surface 
epithelium in more distal airways could ameliorate distal airway disease and thereby affect the 
clinical course of the disease without necessarily achieving a “cure”.  
 
1.1.4 Stem cells and cell-based therapy for cystic fibrosis lung disease 
In cystic fibrosis two important requisites for a disease to be considered as an ideal candidate for 
gene therapy are fulfilled: it is a monogenic disorder and the main affected organ is the lung, which 
is relatively accessible via topical administration. Although initially successful gene transfer in 
animal models generated enthusiasm, later studies in primate models and in patients were 
discouraging (Sueblinvong et al, 2007). This has led to a search for alternative approaches including 
the use of stem cell populations. CF is a potential model disease for stem cell therapy because of the 
persistent lung inflammation that leads to damage and remodeling, and can promote engraftment of 
stem cells (Piro et al, 2008).  
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A developing potential therapeutic approach for CF and other lung diseases has been stimulated by 
recent reports demonstrating that several cell populations derived from adult bone marrow or from 
umbilical cord blood, including stromal derived mesenchymal stem cells (MSCs), endothelial 
progenitor cells, and circulating fibrocytes, can localize to a variety of organs and acquire 
phenotypic and functional markers of mature organ-specific cells (Korbling and Estrov, 2003; 
Prockop, 2003; Herzog et al, 2003; Weiss et al, 2006). Whether the cells used in these studies were 
truly „„stem‟‟ cells has not been rigorously demonstrated, and some of these studies are 
controversial (Weiss et al, 2006; Wagers et al, 2002; Neuringer and Randell, 2006). Additionally, 
embryonic stem cells can be induced in culture to develop markers of lung epithelium, and a human 
embryonic stem cell line containing the F508del CFTR mutation has been established (Pickering et 
al, 2005; Denham et al,  2006; Mateizel et al, 2006; Coraux et al, 2005). Investigations using 
human embryonic stem cells are limited by scientific, ethical, and political considerations (Brown et 
al, 2006). In lung, in vitro studies demonstrate that adult marrow–derived and cord blood–derived 
cells can be induced to express markers of airway or alveolar epithelial phenotype (Weiss et al, 
2006; Neuringer and Randell, 2006). In some cases, the acquisition of functional phenotype in vitro 
has been demonstrated. For example, human marrow–derived MSCs co-cultured with primary 
human airway epithelial cells express several airway epithelial markers, including cytokeratin, 
occludin, and CFTR (Wang et al, 2005). MSCs obtained from the bone marrow of patients who 
have CF and transduced ex vivo to express wild-type CFTR partly correct defective CFTR-
mediated chloride conductance when co-cultured with primary airway epithelial cells obtained from 
patients who have CF (Wang et al, 2005). Parallel in vivo studies in mouse models have suggested 
that bone marrow– derived cells can localize to lung and acquire phenotypic markers of airway and 
alveolar epithelium, vascular endothelium, and interstitial cells (Weiss et al, 2006; Neuringer and 
Randell, 2006). In humans, lung specimens from clinical bone marrow transplant recipients 
demonstrate chimerism of epithelial and endothelial cells (Suratt et al, 2003; Mattsson et al, 2004). 
Similarly, lung specimens from lung transplant patients demonstrate chimerism of lung epithelium 
(Kleeberger et al, 2006; Spencer et al, 2005). Many of these reports are based on sex-mismatched 
transplantation and in situ demonstration of Y chromosome–containing donor marrow–derived cells 
in recipient lungs by fluorescence in situ hybridization followed by immunohistochemical 
phenotyping of the donor-derived cells (Trotman et al, 2007). As analytical techniques have 
improved, despite earlier reports demonstrating substantial engraftment with donor-derived cells, 
more recent reports demonstrate that only small numbers of transplanted adult marrow–derived 
cells engraft in recipient lungs, particularly in airway or alveolar epithelium (Weiss et al, 2006; 
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Chang et al, 2005). This includes only rare engraftment and CFTR expression in airway and 
intestinal epithelium after transplantation of adult marrow–derived cells containing wild-type CFTR 
to CFTR knockout mice (Loi et al, 2006; Bruscia et al, 2006). Further, the mechanisms by which 
marrow-derived or cord blood–derived cells are recruited to lung and acquire airway or alveolar 
epithelial phenotype are poorly understood. Thus, although airway or alveolar epithelial 
engraftment by marrow-derived cells occurs, it is rare and has not been linked to potential 
therapeutic benefit. Despite rare engraftment of airway or alveolar epithelium, there are an 
increasing number of studies demonstrating a functional role of adult marrow–derived cells in the 
mitigation of lung injury. This has been described in models of lung inflammation, emphysema, and 
fibrosis (Ishizawa et al, 2004; Yamada et al, 2004; Ortiz et al, 2003). These effects have been 
observed with several cell populations, including MSCs. Systemic administration of MSCs 
immediately after intratracheal bleomycin administration decreased subsequent lung fibrosis and 
collagen accumulation (Ortiz et al, 2003). Another population of marrow-derived cells contributed 
to airway epithelial re-epitheliazation in a tracheal allograft model (Gomperts et al, 2006). 
Conversely, marrow-derived cells, including circulating fibrocytes, may contribute to the 
development of lung fibrosis (Epperly et al, 2003; Hashimoto  et al, 2004; Schmidt et al, 2003). 
The mechanisms for these effects are unknown but strongly suggest that marrow-derived cells can 
participate in lung injury and repair. More recently, several reports have demonstrated that 
intratracheal, rather than systemic, administration of adult marrow–derived MSCs can mitigate lung 
injury. Intratracheal administration of MSCs 4 hours after intratracheal endotoxin administration 
decreased mortality, pulmonary edema, and BALF levels of the proinflammatory cytokines tumor 
necrosis factor–a and MIP-1b compared with endotoxin-only–treated mice (Gupta et al, 2006). 
There was little structural engraftment of airway or alveolar epithelium by the MSCs. Comparably 
systemic administration of MSCs to mice with bleomycin-injured lungs decreased levels of 
proinflammatory cytokines and levels of matrix metalloproteinase 2 and 9 in the lungs (Ortiz et al, 
2003). The mechanisms for these effects are unknown, but accumulating data suggest that MSCs 
may have significant immunomodulatory effects in the lung. Whether these cells can be used to 
modulate airway inflammation in CF or whether engraftment of marrow or cord blood–derived cells 
in airway epithelium can be used to correct defective CF airway epithelium are areas of active study 
but have not yielded viable therapeutic strategies. Efforts to better identify and characterize resident 
progenitor cells and progenitor cell niches in the upper and lower airways and 
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in alveoli may provide targets for sustained gene expression. Evidence in mice and humans suggests 
that there are regional niches of airway and submucosal gland progenitor cells with different 
phenotypic and functional characteristics (Reynolds et al, 2000; Hong et al, 2001; Giangreco et al, 
2002; Schoch et al, 2004; Engelhardt et al, 1995; Zepeda et al, 1995; Hollande et al, 2004). 
Alveolar epithelium in patients who have CF contains primitive cuboidal cells that express 
primitive cell markers, including thyroid transcription factor and cytokeratin 7. This suggests that 
endogenous progenitor cell pathways in CF lungs may be altered, but this has not been extensively 
investigated. Progress toward identifying a specific pluripotential stem cell in the airway may allow 
for targeting with gene transfer vectors that provide sustained expression. Targeting of endogenous 
progenitor cells also requires methods to overcome the barriers to gene delivery.  
 
1.2 Regenerative medicine  
Recently, in addition to the current therapeutic modalities, such as medical therapy, surgery, organ 
transplantation, and mechanical assist devices, regenerative medicine is being focused on as a 
potential alternative to complicated tissue/organ transplantation. Regenerative medicine is a newly 
emerging and multidisciplinary field which draws on biology, medicine and genetic manipulation 
for the development of strategies aimed at maintaining, enhancing or restoring the function of 
tissues or organs which has been compromised through disease or injury. Due to their ability to 
differentiate toward multiple cell types, stem cells will undoubtedly play a key role in the 
development of such strategies. 
People with end-stage lung diseases could potentially benefit from regenerative medicine since the 
current best treatment available is lung transplantation. Regenerative medicine offers great potential 
for future medical care.  
 
  1.2.1 Tissue engineering 
Tissue engineering is an innovative technology employing biomedically engineered cells and 
scaffolds to create artificial organs and tissues such as skin, bone and heart valves. The most 
challenging aspect of tissue engineering is the creation of an artificial organ/tissue that has similar 
biological composition and physiological functions to the native organ/tissue. This may be why 
tissue engineering remains a colossal challenge in the lung. Recapitulating the cellular components 
involved in immunity, the mechanical functions of breathing and the intricate physiology of gas 
exchanges are factors that overwhelm tissue engineering efforts in the lung. Although no one has 
ever been able to generate an entire lung through tissue engineering approaches, a few studies have 
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shown some success in creating parts of the large airways (Choe et al, 2006; Yang et al, 2003) or 
lung parenchyma (Chen et al, 2005; Shigemura et al, 2006). The combination of stem/progenitor 
cells with bioengineering has shown promise in generating “lung equivalents” comprised of lung-
like cells (Andrade et al, 2007; Coraux et al, 2005; Cortiella et al, 2006) since stem cells have great 
potential to differentiate into most if not all cell types. Bioengineering of lung cells in vitro with 
embryonic stem cells (ESC) (Rippon et al, 2006) is another promising effort for cell-based 
therapies. Although tissue engineering is a highly desirable long-term goal for lung regeneration, it 
remains rudimentary.  
 
1.2.2 Gene therapy 
Gene therapy involves the insertion of a therapeutic gene into cells to treat diseases, that engage 
replacing a mutant allele with a normal one. The discovery of CFTR has stimulated intensive 
research into therapeutic gene therapy approaches to replace the defective gene in CF. The first 
clinical trial for CF began in 1992 where adenovirus-mediate gene transfer effectively restored Cl
-
 
conductance in the nasal epithelium of cystic fibrotic patients (Zabner et al, 1993). Since then, 
much progress has been made in terms of using gene therapy as a technique to replace the defective 
gene in affected cells (Alton et al, 1993; Chow et al, 1997; Drumm et al, 1990; Flotte et al, 1993; 
Flotte et al, 2003; Koehler et al, 2003; Moss et al, 2004). Many animal models of cystic fibrosis 
have also been created to evaluate and delineate the pathogenesis of the disease. The first and most 
common is the CFTR knockout mice model which most closely resembles certain features of the 
disease in humans (Snouwaert et al, 1992). Various gene delivery methods such as adenovirus 
(Johnson et al, 1996; Zabner et al, 1993), retrovirus (Olsen et al, 1992) and adeno-associated 
viruses (Flotte et al, 1993; Flotte et al, 2003; Moss et al, 2004) have been studied extensively for 
treatment of CF. These methods of gene delivery have proven to be somewhat effective, yet 
concerns remain over the long-term efficacy and safety of using viral-based vectors in humans. 
Liposomes have shown limited success in gene delivery (Alton et al, 1993; Noone et al, 2000; 
Yatvin, 2002). These vectors are unstable and have poor transfection efficiencies in vivo 
(McLachlan et al, 1995). Extracellular and intracellular barriers hinder successful gene transfer. The 
lack of viral receptors on the apical surface of the airway epithelium for example limits viral 
transfection with the transgene to the target cell when delivered topically through the airways. 
Systemic delivery increase risks of multiorgan toxicity and most often results in transfection of the 
respiratory epithelium than the airway epithelium. Furthermore, the inability of vectors to evade the 
host immune response limits the efficiency of successful transfection. Retroviral and adenoviral 
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methods of gene delivery are often accompanied by significant inflammatory responses due to these 
vectors. The random delivery of the transgene by viruses poses another risk of insertional 
mutagenesis which can affect the expression of other important genes. In addition, a study has 
shown the presence of viral genetic material incorporated into host genome (Eissa et al, 1994). In 
this study, about 13% of the E1 genes (responsible for viral replication) were found in the affected 
epithelium of patients that received adenovirus-mediated gene transfer of CFTR. Intracellular 
barriers include cytoplasmic clearance mechanisms (eg. Ubiquination and cytoplasmic protease 
digestion) that can digest the transgene preventing it from entering the nuclei (Kitson et al, 1999). 
Uptake of DNA into the nuclear compartment may also be an important barrier in terminally 
differentiated, non-dividing cells. Although attempts to increase nuclear uptake of oligonucleotides 
and plasmids by adding nuclear localization signals to the DNA (Zanta et al, 1999) have shown 
some improvements, sustained gene expression may remain a problem in slow-cycling cells.  
 
1.2.3 Cell-based gene therapy 
Cell-based gene therapy is another field of regenerative medicine. It promises the use of a host‟s 
own cells, after genetic manipulations, to deliver the therapeutic protein/DNA to the site of injury 
for repair and/or regeneration. Since it uses the host‟s own cells as vehicles for gene delivery, it 
avoids the immunological barriers that are often associated with viral-based vectors. In addition, 
this cell-based approach eliminates the risk of DNA degradation as observed in naked-DNA 
delivery.  
 
1.2.4 Stem cells 
Stem cells (see section 1.3) have received incredible attention within the past decade. Numerous 
studies have suggested the potential of stem cells to regenerate tissue/organs. The mechanism of 
stem cell-mediated regeneration remains controversial. While some studies suggest stem cells 
contribute to tissue cell lineages upon homing and lodging in the injured site by transdifferentiation 
and/or fusion (Kotton et al, 2001; Krause et al, 2001; Nygren et al, 2004; Reinecke et al, 2004; 
Rizvi et al, 2006; Shi et al, 2004; Wang et al, 2005), others suggest that stem cells do not contribute 
to tissue cell lineages but provide a pro-regenerative milieu (Fazel et al, 2006) for repair of injured 
tissue with local progenitor cells or by attenuation of immune/inflammatory responses to injury 
(Ayach et al, 2006a; Ortiz et al, 2007; Xu et al, 2007b). Functional tissue have been created through 
the use of stem cell manipulation/transplantation such as repair of the infarcted myocardium (Fazel
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 et al, 2005), axonal regeneration following spinal cord injury (Kim et al, 2007), alveolar 
regeneration (Ishizawa et al, 2004a) and the intestinal epithelium (Bruscia et al, 2006).  
 
1.2.5 Rationale for stem cell-mediated regenerative medicine 
The best current treatment for lung diseases such as end-stage lung diseases or CF is lung 
transplantation. Not only is a lack of organ donation an obstacle to treatment, but also graft 
rejection/failure is a major limitation for long-term success in lung transplantation. Stem cell-
mediated regenerative medicine offers great promise for treatment of diseases that involves cell-
based gene correction and replacement of a particular cell such as in cystic fibrosis. Successful 
long-term restoration of continuously self-renewing tissues such as the lung depends on the use of 
self-renewing stem cells. In addition, the pluripotent/multipotent differentiation capabilities of stem 
cells allows for potential functional replacement and restoration of tissue components. Therefore 
stem cells provide appropriate targets for prospective cell-based gene therapies and cell replacement 
strategies. 
 
1.3 Stem cells 
1.3.1 Stem cells 
A stem cell is defined as an undifferentiated cell capable of long-term self renewal and multi-
lineage differentiation potential. Under homeostatic conditions, stem cells are slow-cycling and/or 
quiescent. Upon stimulation such as during tissue injury, stem cells can give rise to daughter cells 
called transient amplifying (TA) cells that generates sufficient specialized progenies for tissue 
maintenance. Stem cells can undergo symmetric cell division whereby a stem cell divides and gives 
rise to 2 daughter stem cells identical to itself. Stem cells can also undergo asymmetric cell division 
in which one of the daughter cell loses some of the stem cell characteristics of the parent cell and 
begins the process of cell lineage commitment. 
 
1.3.2 Progenitor cells and transient amplifying cells 
A progenitor cell has more limited differentiation potential but may still be multipotent. Progenitor 
cells may have self-renewal capacity but, unlike stem cells, progenitor cells do not have unlimited 
self-renewal capabilities. Transient amplifying cells are intermediary cells between a stem cell and 
its final differentiated progeny. These cells are highly proliferative and can give rise to one or more 
differentiated cell type. It remains unclear whether TA cells are the same as progenitor cells. 
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1.3.3 Stem cell characteristics 
1.3.3.1 Self-renewal 
Self-renewal is defined as the ability of a cell to give rise to daughter cells that retain the properties 
of the parent cell. The process has been rigorously studied and involves several intrinsic signals 
such as the proto-oncogene Bmi-1 (Park et al, 2003) which encodes for polycomb group complex 
proteins that repress genes involved in differentiation, the transcription factor HoxB4 (Sauvageau et 
al, 1995), and signaling molecules Notch (Varnum-Finney et al, 2000), Sonic hedgehog (Bhardwaj 
et al, 2001) and Wnt (Austin et al, 1997; Nemeth and Bodine, 2007; Reya et al, 2003). Activation of 
Wnt signaling is also important in mesenchymal stem cells proliferation and mesenchymal lineage 
specification (Etheridge et al, 2004). Telomerase activity is associated with increased cell 
proliferation. Telomeres are regions of highly repetitive DNA found at the end of linear 
chromosomes that cannot be replicated by the DNA polymerase complex. Therefore, with every 
replication of the chromosome, it will lose a small portion of the genetic information. Telomerase is 
a subgroup of reverse transcriptase enzymes known as TERT that can extend telomeres. The 
decrease in telomerase activity has been linked with aging (Hornsby, 2007) while an increase in 
telomerase activity has been associated with cancer (Deng and Chang, 2007). 
 
1.3.3.2 Development of diverse phenotypes 
Cells can develop and mature through a lineage program through many pathways. The most 
common pathway is differentiation of an immature cell such as a progenitor cell into a cell with 
more specialized function(s) and greater level of complexity. The process may require several 
rounds of cell division going through several intermediary cell types before becoming the fully 
mature cell type. Transdifferentiation occurs when a cell becomes another cell type outside of its 
already established differentiation pathway. Dedifferentiation is the process by which a terminally 
differentiated cell reverts to a cell of an earlier developmental stage. Cell fusion may be another 
pathway by which a cell acquires the phenotype of another cell. Bone marrow cells have been 
shown to give rise to lung epithelial, cardiomyocyte, and muscle cells by cell fusion with resident 
tissue cells (Nygren et al, 2004; Shi et al, 2004; Spees et al, 2003; Terada et al, 2002; Wong et al, 
2007). 
Epigenetic regulation plays a role in stem cell differentiation. The three major epigenetic 
mechanisms that have been shown to control stem cell differentiation are DNA methylation,  
Histone modification, and non-coding RNA-mediated regulatory events. 
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DNA methylation occurs mainly at CpG dinucleotides. Hypermethylation is associated with gene 
silencing whereas hypomethylation is associated with gene expression. DNA methylation is 
primarily associated with parental-specific imprinting during gametogenesis (Kaneda et al, 2004) 
and silencing of genes on the inactivated X-chromosome (Maatouk et al, 2006) but it also involved 
in cell differentiation (Takizawa et al, 2001). Post-translational modification of histones by 
acetylation of lysine residues on the amino end of the chromatin is another mechanism that controls 
cells differentiation (Cheung et al, 2000). Lysine acetylation by histone acetyltransferases (HATs) 
is associated with gene activation, whereas deacetylation with histone deacetylases (HDACs) is 
associated with gene inactivation. Histone methylation however is associated with transcriptional 
repression whereas demethylation is associated with transcriptional activation. Finally, post-
transcriptional gene regulation by small non-coding RNAs or microRNAs is a newly emerging 
epigenetic mechanism. These RNAs are distinct from siRNA (small interfering RNA) in that they 
are transcribed products produced from RNA-coding genes. These microRNAs can then bind to 
mRNA sequences that share some complementary sequences to the mRNA preventing the mRNA 
from being translated. The outcome is reduced expression of a particular group of genes. 
MicroRNAs have been shown to be involved in embryonic stem cells development (Chen et al, 
2004).  
 
1.3.3.3 Plasticity 
Plasticity is defined as the ability of a cell to produce progenies that cross lineage  boundaries. 
There is a hierarchy of stem cell plasticity. Totipotent cells can give rise to all cells in the body as 
well as the placenta and embryonic cells (ESC and germ cells). These cells are considered to be the 
most primitive stem cells and exists in the first few cell divisions of the fertilized egg. Pluripotent 
stem cells are descendents of totipotent stem cells and can give rise to cells of all germ layers. 
These cells are found in the inner cell mass of the blastocyst and while ESC are the best known, 
there are others such as primordial germ cells, and possibly certain adult stem cells such as bone 
marrow-derived very small embryonic-like stem cells. Multipotent stem cells have more restricted 
differentiation potential than pluripotent stem cells. As the progeny become more lineage-
committed or determined, the ability of the cell to give rise to various cell lineages becomes 
restricted down to the unipotent progenitor cell which can only give rise to one particular cell 
phenotype. It has long been felt that multipotent stem cells can only give rise to cells within a 
lineage. However, there is growing evidence that cells that were once thought to be multipotent can 
give rise to cells outside of their traditional lineage commitment.  
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 1.3.4 Types of stem cells 
  1.3.4.1 Embryonic stem cells 
Embryonic stem cells (ESC) are pluripotent cells derived from the inner cell mass of the blastocyst 
within the first 5-7 days after an egg is fertilized by sperm (Thomson et al, 1998). In other words, 
they can produce cells from all three germ layers: endoderm, ectoderm and mesoderm. These cells 
transiently exist in the developing embryo. These cells can be isolated and cultured ex vivo as cell 
aggregates called embryoid bodies and maintained in an undifferentiated state indefinitely through 
artifactual conditions using leukemia inhibitory factor containing media and on feeder layers. A 
recent study showed that ESC can also be cultured as single cell suspensions in an undifferentiated 
state using a Rho-associated kinase inhibitor (Watanabe et al, 2007). ESC express several markers 
associated with self-renewal and pluripotency namely OCT-4, Rex-1, Nanog, SSEA-1 (mouse) and 
SSEA3/4 (humans) and the presence of alkaline phosphatase and telomerase activity (Armstrong et 
al, 2005; Babaie et al, 2007; Pan and Thomson, 2007; Wobus et al, 1984). ESC has been shown to 
differentiate into cells of neuronal (Bibel et al, 2004), cardiac (Guo et al, 2006; Reppel et al, 2004), 
retinal (Tabata et al, 2004), hepatic (Shirahashi et al, 2004), and lung epithelial 
(Samadikuchaksaraei et al, 2006) cells. 
 
1.3.4.2 Adult stem cells 
Adult stem cells are multipotent in that they have less self-renewal capacity and their potential for 
differentiation was believed to be limited to their tissue of origin. However, recent evidence have 
suggested that certain adult stem cells may have pluripotent characteristics (Devine et al, 2003; 
Jiang et al, 2002a; Krause et al, 2001; Kucia et al, 2006a). 
 
 1.3.5 Stem cell challenges 
Stem cells isolated from adults or developing embryos are currently thought to be a source of cells 
for regenerative medicine. However, despite their therapeutic potential, both adult and ES cells 
present a number of challenges associated with their clinical application and are thus not in general 
use yet (Smith et al, 2006). For example, although adult stem cells can be directly isolated from the 
patient and are therefore immunologically compatible with the patient, they are generally hard to 
isolate and grow in culture; and moreover, transplantation of a sufficient number of cells to adult 
tissue needs a large-scale cell supply. In contrast, human ES cells can proliferate very fast in culture 
and differentiate into cells of all adult tissues, but additional research is required to control the
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 growth and to overcome the risks of tumor formation by undifferentiated ES cells and graft 
rejection. It is also necessary to resolve the ethical issues surrounding the use of materials from 
embryos.  
Embryonic stem cells require destruction of the human embryo for their procurement and are 
associated with a high rate of tumor induction (teratoma) following transplantation, while 
mesenchymal stromal cells from bone marrow carry with them a risk of viral infection (Eichna et 
al. 2008), and the  differentiation capacity of these cells has been seen to decrease with donor age 
(D’Ippolito et al, 1999; Mareschi et al, 2006). The need therefore remains to identify a source of 
stem cells that is safe, easily accessible, provides a high cell yield and for which cell procurement 
does not provoke ethical debate. 
Recently, the multipotent differentiation ability of amnion-derived cells has been reported and these 
cells have attracted a lot of attention as a cell source for cell transplantation therapy.  
In addressing the complex scenario described above, several groups have recently turned their 
attention to the human term placenta as a possible source of progenitor/stem cells. The fact that 
placental tissues originate during the first stages of embryological development supports the 
possibility that these tissues may contain cells which have retained the plasticity of the early 
embryonic cells from which they derive. Meanwhile, the fact that the placenta is fundamental for 
maintaining fetomaternal tolerance during pregnancy suggests that cells present in placental tissue 
may have immunomodulatory characteristics. These two key aspects make cells from placenta good 
candidates for possible use in cell therapy approaches, with the possibility of providing cells that are 
capable of differentiating into multiple different cell types, and which also display immunological 
properties that would allow their use in an allo-transplantation setting. Furthermore, given that the 
placenta is generally discarded after birth, this tissue is available in large supply, the recovery of 
cells from this tissue does not involve any invasive procedures for the donor, and their use does not 
pose any ethical problems. 
The amniotic membrane has already been applied in medicine, for example, in burn lesion 
treatment, surgical wound covering to avoid collusion (Trelford et al, 1979), and ocular surface 
reconstitution, although uncertainty remains regarding the mechanism of its effects.  
 
1.4 The placenta   
1.4.1 Placental Compartments 
The fetal adnexa is composed of the placenta, fetal membranes, and umbilical cord. The term 
placenta is discoid in shape with a diameter of 15–20 cm and a thickness of 2–3 cm. From the 
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margins of the chorionic disc extend the fetal membranes, amnion and chorion, which enclose the 
fetus in the amniotic cavity, and the endometrial decidua. The chorionic plate (Fig. 7) is a 
multilayered structure that faces the amniotic cavity.  
It consists of two different 
structures: the amniotic membrane 
(composed of epithelium, compact 
layer, amniotic mesoderm, and 
spongy layer) and the chorion 
(composed of mesenchyme and a 
region of extravillous proliferating 
trophoblast cells interposed in 
varying amounts of Langhans 
fibrinoid, either covered or not by 
syncytiotrophoblast). Villi originate 
from the chorionic plate and anchor 
the placenta through the trophoblast 
of the basal plate and maternal endometrium. From the maternal side, protrusions of the basal plate 
within the chorionic villi produce the placental septa, which divide the parenchyma into irregular 
cotyledons (Fig. 7). Some villi anchor the placenta to the basal plate, whereas others terminate 
freely in the intervillous space. Chorionic villi present with different functions and structure. In the 
term placenta, the stem villi show an inner core of fetal vessels with a distinct muscular wall and 
connective tissue consisting of fibroblasts, myofibroblasts, and dispersed tissue macrophages 
(Hofbauer cells). Mature intermediate villi and term villi are composed of capillary vessels and thin 
mesenchyme. A basement membrane separates the stromal core from an uninterrupted 
multinucleated layer, called syncytiotrophoblast. Between the syncytiotrophoblast and its basement 
membrane are single or aggregated Langhans cytotrophoblastic cells, commonly called 
cytotrophoblast cells. Fetal membranes continue from the edge of the placenta and enclose the 
amniotic fluid and the fetus. The amnion is a thin, avascular membrane composed of an epithelial 
layer and an outer layer of connective tissue, and is contiguous, over the umbilical cord, with the 
fetal skin. The amniotic epithelium (AE) is an uninterrupted, single layer of flat, cuboidal and 
columnar epithelial cells in contact with amniotic fluid. It lies on top of a mesodermal layer 
consisting of an upper acellular compact layer and a deeper layer containing dispersed fibroblasts. 
Figure 7- Schematic section of the human term placenta. During 
placenta formation, from the maternal side, protrusions of the basal plate 
within the chorionic villi produce the placental septa, which divide the 
parenchima into irregular cotyledons. Each cotyledon contains several 
villi, which originate from the chorionic plate. Fetal blood vessels are 
located within the branches of the villi. 
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The chorionic membrane consists of a mesodermal layer (AM) and a layer of extravillous 
trophoblast cells. (Fig. 8).   
In the amniotic mesoderm closest to the epithelium, an acellular compact layer is distinguishable, 
composed of collagens I and III and fibronectin. Deeper in the AM, a network of dispersed 
fibroblast-like mesenchymal cells and rare macrophages are observed. Very recently, it has been 
reported that the mesenchymal layer of amnion indeed contains two subfractions, one having a 
mesenchymal phenotype, referred as amniotic mesenchymal stromal cells, and the second 
containing monocyte-like cells (Magatti et al, 2007). A spongy layer of loosely arranged collagen 
fibers separates the amniotic and chorionic mesoderm (Fig. 8). The chorionic membrane (chorion 
leave) consists of mesodermal and trophoblastic regions (Fig. 8). Chorionic and amniotic mesoderm 
are similar in composition. A large and incomplete 
basal lamina separates the chorionic mesoderm from 
the extravillous trophoblast cells. The latter, similar to 
trophoblast cells present in the basal plate, are 
dispersed within the fibrinoid layer and express 
immunohistochemical markers of proliferation. The 
Langhans fibrinoid layer usually increases during 
pregnancy and is composed of two different types: a 
matrix type on the inner side (more compact) and a 
fibrin type on the outer side (more reticulate). At the 
edge of the placenta and in the basal plate, the 
trophoblast interdigitates extensively with the deciduas 
(Cunningham et al, 1997; Benirschke and Kaufmann, 2000). 
 
1.4.2 Embryological Development 
In humans, by days 6–7 after fertilization (during the implantation window), the blastocyst implants 
and placenta development begins. At this stage, the blastocyst is flattened and composed of an outer 
wall (trophoblast) that surrounds the blastocystic cavity. A small group of larger cells, the inner cell 
mass, is apposed to the inner surface of the trophoblastic vesicle. The embryo, umbilical cord, and 
amniotic epithelium are derived from the inner cell mass. As the blastocyst adheres to the 
endometrium, invading trophoblasts erode the decidua, facilitating implantation of the blastocyst. 
By 8–9 days after fertilization, trophoblastic cells at the implanting pole of the blastocyst proliferate 
robustly, forming a bilayered trophoblast. The outer of the two layers becomes the 
Figure 8- Cross-sectional representation of 
human fetal membranes (amnion and chorion). 
Abbreviations: AE; amniotic epithelium; AM, 
amniotic mesoderm; CM, chorionic mesoderm; 
CT, chorionic trophoblast. 
 
INTRODUCTION: The Placenta 
 
 
 
25 
syncytiotrophoblast by fusion of neighboring trophoblast cells, whereas the inner cells 
(cytotrophoblast) remain temporally unfused. The proliferating cytotrophoblasts and the 
syncytiotrophoblasts give rise to a system of trabeculae intermingled with hematic lacunae. From 
these trabeculae are generated the primordial villi that are distributed over the entire periphery of 
the chorionic membrane. Villi in contact with the decidua basalis proliferate to form the leafy 
chorion or chorion frondosum, whereas villi in contact with the decidua capsularis degenerate into 
the chorion leave. At day 8–9 after fertilization, the inner cell mass differentiates into two layers: 
the epiblast and the hypoblast. Subsequently, from the epiblast, small cells that later constitute the 
amniotic epithelium appear between the trophoblast and the embryonic disc and enclose a space that 
will become the amniotic cavity. On the opposite side, between the hypoblast and cytotrophoblast, 
the exocoelomic membrane and its cavity modify to form the yolk sac. The extraembryonic 
mesoderm arranges into a connective tissue that surrounds the yolk sac and amniotic cavity, giving 
rise to amniotic and chorionic mesoderm (Fig. 9).  
Gastrulation, the process through which the bilaminar disc differentiates into the three germ layers 
(ectoderm, mesoderm, and endoderm) and develops a defined form, with a midline and cranio-
caudal, right-left, and dorsal-ventral body axes, occurs during the 3rd week after fertilization 
(Benirschke and Kaufmann, 2000; Moore et al, 1998).  
 
 
 
 
 
1.4.3. Basic structure and function of amniotic membrane 
The amniotic membrane is a tissue of fetal origin and is composed of three major layers: a single 
epithelial layer, a thick basement membrane, and an avascular mesenchyme (Fig. 10) (Benirschke 
Figure 9 – Diagram of embryogenesis from fertilization to gastrulation 
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and Kaufmann, 2000). There are no nerves, muscles, or lymphatics in the amnion. It is adjacent to 
the trophoblast cells and lines the amniotic cavity. It can be easily separated from the underlying 
chorion, with which it never truly fuses at the cellular level. The amnion obtains its nutrition and 
oxygen from the surrounding chorionic fluid, the amniotic fluid, and the fetal surface vessels. 
One of the basic functions of the amniotic 
membrane is to provide the developing 
embryo with protection against desiccation 
and an environment for suspension in which 
the embryo can grow without distortion by 
pressure from surrounding structures. The 
amnion also plays an important role during 
parturition. In the initiation and  maintenance 
of uterine contraction, prostaglandins play a 
pivotal role. The amniotic epithelium is not 
only one of the main sources of 
prostaglandins, especially prostaglandin E2 
(Okazaki et al, 1981), but also expresses 
prostaglandin-biosynthesis enzymes such as 
phospholipase, prostaglandin synthase, and 
cyclooxygenase (Bryant-Greenwood et al, 
1987). Moreover, these enzymes are regulated by human chorionic gonadotropin (hCG), the 
receptors of which are found on the amniotic epithelium (Toth et al, 1996). Amniotic epithelium is 
metabolically highly active throughout gestation, and it is also responsible for regulating the pH of 
the amniotic fluid, keeping it constant at about 7.10.  
From a structural perspective, the amniotic cells are connected to each other by numerous 
desmosomes; however, tight junctions occluding the lateral intercellular spaces and thus limiting 
paracellular transport can not be observed between the cells (King, 1982). Consequently, the 
intercellular clefts may represent an effective route for paracellular transfer of macromolecules. The 
basal lamina contains large quantities of proteoglycans, rich in heparan sulfate, that may serve as a 
permeability barrier to amniotic macromolecules (King, 1985). Wolf et al. reported that in the 
amniotic epithelium, the specialized arrangement of intracellular cytoskeletal filaments such as 
actin, α- actinin, spectrin, ezrin,  cytokeratins, vimentin, and desmoplakin indicates their role in the 
structural integrity and modulation of cell shape as well as in junctional permeability (Wolf et al, 
Figure 10 - Histology of amnion. Normal human placenta 
sample as sectioned and stained with hematoxylin and eosin. 
In the left panel, the three major components, amnion, 
chorion, and decidua, were shown. The arrow indicates the 
coarse intermediate layer of connective tissue. The right panel 
shows photos of membrane “before” and “after” 
trypsinization. Only amniotic epithelial cells were dissociated 
by trypsinization. Although not shown, subsequent 
collagenase digestion would release the amniotic 
mesenchymal cells from the connective tissue. 
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1991). Laminin is one of the main components of the basement membrane and it critically 
contributes to cell differentiation, cell shape and movement, maintenance of tissue phenotypes, and 
promotion of tissue survival via cell surface receptors such as integrins and dystroglycans (Akashi et 
al, 1999). 
 
1.4.4 Pluripotency of amnion-derived cells 
Regarding differentiation potential, it is expected that the amniotic membrane might maintain 
pluripotent properties. Developmentally, the inner cell mass of the blastocyst, from which ES cells 
are derived, gives rise to both the epiblast (from which the embryo is derived) and the hypoblast 
(from which the yolk sac is derived). From this epiblast (embryonic ectoderm) the amniotic 
epithelial layer (amniotic ectoderm) is derived on about the 8th day after fertilization, while the 
mesenchymal cells (amniotic mesenchyme) are from extraembryonic mesoderm of the primitive 
streak (Enders and King, 1988). Considering that the epiblast also gives rise to all of the germ 
layers of the embryo, amniotic epithelial cells are also expected to give rise to three germ layers. 
Moreover, the amniotic epithelial layer is derived before gastrulation. Considering that pluripotent 
embryonal carcinoma cells can only be generated from cells derived before gastrulation (Diwan and 
Stevens, 1976), indicating the importance of gastrulation in the differentiation and specification of 
cell fate, it is expected that amniotic epithelial cells might maintain the plasticity existing in the 
cells in the pregastrulation embryo (Miki et al, 2005). Several reports demonstrated that both human 
amniotic epithelial cells (hAECs) and amniotic mesenchymal stromal cells (hAMSCs) express 
several stem cell markers such as octamer-binding transcription factor (OCT)-4, which is 
specifically expressed in ES cells and germ cells; GATA-4, which is a marker of definitive 
embryonic and visceral (extra-embryonic) endoderm; hepatocyte nuclear factor-3β (HNF-3β), 
which is a marker of definitive endoderm; nestin, which is an intermediate protein and a neural stem 
cell-specific marker; and nanog (Miki et al, 2005; Wei et al, 2003; Takashima et al, 2004). These 
facts suggest that  hAECs and hAMSCs possess pluripotency.  
 
1.4.5 Anti-inflammatory and low immunogenic characteristics of amniotic membrane 
/amnion-derived cells 
Amniotic membranes/amnion-derived cells have been considered to be suitable tissue or cells for 
allotransplantation, based on their anti-inflammatory effects and low immunogenicity. Much 
evidence supporting these ideas has been accumulated. As to anti-inflammatory effects, Hao et al. 
reported that both hAECs and hAMSCs express various antiangiogenic and anti inflammatory 
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proteins such as interleukin (IL)-1 receptor antagonist; tissue inhibitors of metalloproteinase 
(TIMPs)-1, -2, -3, -4; and IL-10 (Hao et al, 2000). Amniotic membrane stromal matrix markedly 
suppressed lipopolysacharide-induced upregulation of both IL-1α and -1β in human corneal limbal 
epithelial cells cultivated on it (Solomon et al, 2001). In addition, amniotic membrane stromal 
matrix also suppressed DNA synthesis and subsequent differentiation of myofibroblasts obtained 
from human cornea and limb, through suppressing the TGF-β signaling system (Tseng et al, 2009). 
hAECs expressed mRNA of tumor necrosis factor (TNF)α, Fas ligand, TNF-related apoptosis-
inducing ligand (TRAIL), TGF-β, and macrophage migration-inhibitory factor (MIF) (19). The 
supernatants from hAECs cultures inhibited the chemotactic activity of neutrophils and 
macrophages toward macrophage inflammatory protein 2, reduced the proliferation of T- and B-
cells after mitogenic stimulation, and induced apoptosis of T and B cells, but not of corneal 
epithelial cells (Li et al, 2005), and also suppressed corneal neovascularization and migration of 
major histocompatibility complex (MHC) class II+ antigen-presenting cells (APCs) in cauterized 
mouse corneas (Kamiya et al, 2005). As to antibacterial properties, human amniotic membrane 
reduces bacterial counts and promotes healing of infected wounds (Talmi et al, 1991). As to the low 
immunogenicity, clinical signs of acute rejection were not observed when amniotic membrane was 
transplanted into volunteers (Akle et al, 1981). The expression level of MHC class I antigens is still 
controversial. Although it was reported that HLA-A, -B, -C, and –DR were not detected in cultured 
amniotic epithelium (Adinolfi et al, 1982), the detection of class I antigen in almost all cells in the 
amniotic membrane has been reported since then (Hammer et al, 1997; Kubo et al, 2001). In 
contrast, class II antigen was expressed only in some fibroblasts in human amniotic membrane 
(Kubo et al, 2001). Several studies examined the fate of amniotic membrane grafts. Wang et al. 
(Wang et al, 2006) studied allogeneic GFP+ mouse amniotic membrane grafts heterotopically 
transplanted in the eye. Kubo et al. studied xenotransplanted human amniotic membrane in the eye 
of rats (Kubo et al, 2001). These experiments showed that the fate or allogenicity of amniotic 
epithelial cells depended on the graft site. For example, grafts implanted in the anterior chamber or 
intracornea survived longer than those transplanted on the ocular surface. The authors mentioned 
that because of the short period of viability of donor-derived amniotic epithelial cells grafted on the 
ocular surface, these cells had already lost viability and thus were unable to display enough antigens 
to represent a target for effector CD4+ and CD8+ T cells. As a result, long-term memory of 
sensitization was not acquired (Wang et al, 2006). In addition, from the observation that amniotic 
cells disappeared without a rejection reaction, the authors speculated that the short existence of 
donor derived AE cells on the ocular surface might be due to the process of apoptosis (Kubo et al, 
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2001; Wang et al, 2006). Actually, both hAECs (Li et al, 2005; Runic et al, 1998) and hAMSCs 
(Kubo et al, 2001) were reported to express Fas ligand, which may be easily released from apoptotic 
amniotic cells as the soluble form, and may exert an immunosuppressive effect. Fetal nonclassic 
HLA-G (class Ib antigen) is also expressed in the human amniotic membrane (Hammer et al, 1997; 
Kubo et al, 2001). Because the HLA-G molecule has low polymorphism compared to with class Ia 
antigen, aggression against the fetus is not easily initiated by HLA-G expression in the fetal-
maternal interface. Kubo et al. noted that the expression of HLA-G in the amniotic membrane 
implies two possibilities for the host immune system. First, HLA-G may play the role of a 
tolerogenic peptide, and the host lymphocytes or dendritic cells may be inactivated by HLA-G‟s 
binding to inhibitory receptors. Secondly, HLA-G may be recognized by certain T cells because 
CD8 can bind to HLA-G, and these cells may have a suppressor function (Kubo et al, 2001). The 
expression of these immunosuppressive and immunoregulatory factors may also explain it in part. 
Thus, the problem of immune rejection could be overcome by the use of amniotic membrane. 
However, it was also reported that in presensitized recipient mice and recipients that underwent 
repeated amniotic epithelial implantation, graft survival was markedly shorter than in normal 
recipients, suggesting that fresh allogeneic mouse amniotic epithelium expressed immunogenicity 
(Wang et al, 2006). Therefore, at present, amniotic membrane and the cells derived from it seem to 
be suitable tissue for transplantation because of their anti-inflammatory and low immunogenic 
characteristics; however, in clinical applications, the risk of immunogenicity depending on the 
transplantation-site or of rejection, occurring after repeated amniotic membrane transplantation 
from the same donor, should not be ignored.  
 
1.4.6 Non-tumorigenicity 
There was no evidence of tumorigenicity in humans when isolated amniotic cells were transplanted 
into human volunteers to examine their immunogenicity or into patients in an attempt to correct 
lysosomal storage diseases (Akle et al, 1981; Scaggiante et al, 1987; Sakuragawa et al, 1992). 
However, trisomy mosaicism in the amnion has been reported, especially in amniotic epithelial 
cells. Robinson reported that in 16 (48%) of 33 cases of prenatally diagnosed trisomy mosaicism, 
trisomy was confirmed to be present by molecular analysis of the amnion, although the trisomy was 
absent from most fetal tissues (Robinson et al, 2002). In the cases in which trisomy mosaicism in 
the amnion was not noticed because the fetal tissue was normal, whether or not some biological 
effects would arise in clinical application of these amnions is unclear.  
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1.4.7 Little ethical problems with usage 
Because the amniotic membrane is discarded after parturition, it is easy to obtain without harming 
mothers or babies and would thereby overcome the ethical issues associated with the use of ES 
cells. However, it is still in the possession of the mother, so the use of human amniotic membrane 
had been approved by the Ethics Committee of each Institution and written informed consents had 
been obtained from the mothers. Based on these considerations, human amniotic membrane / 
amnion-derived cells are considered to be a useful biological material and also a novel cell source 
for cell transplantation. 
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2. AIM OF THE STUDY 
The present study aims at evaluating the possibility of using pluripotent stem cells derived from 
human placenta (amnion) in gene and cell therapy for Cystic Fibrosis (CF).  
So far, most experience in preservation of placental tissue derived cells has been gained with cord 
blood, which contains both hematopoietic and mesenchymal stem cells. When cord blood 
transplantation proved effective, many cord blood banks were established, offering collection and 
banking for public (allogenic) or private (autologous or allogenic) use. In contrast to cord blood, 
fetal membrane stem cells are presently preserved mainly for research. However, as these cells gain 
interest for their regenerative and immunomodulatory properties, future medical needs may require 
concomitant application of cord blood and placental cells from the same donor. Stem cells studies 
are in rapid evolution and new sources are investigated in order to find a major “cell plasticity”.  
It is well established that human placenta may represent a reserve of progenitor/stem cells. Because 
the amniotic membrane is discarded after delivery, it is easy to obtain without harming mothers or 
babies and would thereby overcome the ethical issues associated with the use of embryonic stem 
cells. Based on these considerations, human amniotic membrane/amnion-derived cells are 
considered to be a useful biological material and also a novel cell source for cell transplantation. 
Amniotic epithelial cells (hAECs) and amniotic mesenchymal stromal cells (hAMSCs) are known 
to have unique characteristics, such as low level expression of major hystocompatibility complex 
antigens, and a less restricted differentiation potential (Miki and Strom, 2006). In culture, hAECs 
and hAMSCs differentiate into cell types from all the three germ layers. The availability of hAECs 
and hAMSCs and the lack of ethical concerns for this source of stem cells are considered 
advantageous for their widespread use and acceptance. Studies reported the differentiation of 
embryonic stem cells in epithelial tissue composed of basal cells, ciliated cells, intermediate cells, 
nonciliated Clara cells, and similar to the epithelium covering the human bronchioles (Miki et al, 
2009).  
Although gene therapy is easier to perform and has the advantage to transfer Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) wild-type gene into CF airways and to restore the 
correct chloride ion flux through the epithelium, its effect is only temporary. Cell therapy could be a 
more effective treatment because allogenic normal cells and autologous engineered cells may 
reconstitute the damaged epithelium and express the CFTR gene.  
Recently, new cell sources for CF treatment have been characterized: mesenchymal stem cells from 
cord blood (Sueblinvong et al, 2008) and amniotic fluid stem cells (Carraro et al, 2008) can 
differentiate in vitro and in vivo in airway epithelium. The in vivo efficiency of bone marrow stem 
cells to differentiate in airway epithelium is very low (0.01-0.025%) (Piro et al, 2008), as 
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demonstrated by different studies in mice (Loi et al, 2006; Bruscia et al, 2006); in order to facilitate 
cell homing and epithelium differentiation of these cells, pulmonary damage can be induced by 
chemical or physical agents, as bleomycin or X-ray radiation. Recent studies demonstrate that with 
0.1% of donor cells that became respiratory host cells a partial correction of the 
electrophysiological defect has been obtained (Bruscia et al, 2006). On the contrary, other studies 
demonstrate that a higher percentage (6-20%) of corrected cells is needed to revert the defect 
(Farmen et al, 2005).  
In the present study, we evaluated the possibility of obtaining epithelial and mesenchymal stem 
cells from an ethically acceptable source as human placenta. After the isolation of these cells, we 
characterized them and expanded in culture. We finally evaluated the ability of amniotic epithelial 
and mesenchymal cells in differentiating in vitro in airway epithelium for the cure of cystic fibrosis. 
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3. MATERIALS AND METHODS 
 
3.1. Isolation of Human Amniotic Epithelial and Mesenchymal Stromal Cells 
Human amniotic epithelial and mesenchymal stromal cells (hAECs, hAMCs) were isolated from 
term placentas which would normally be discarded after delivery. For sterility purposes, placentas 
were normally obtained from caesarean section; however, theoretically, any placenta should be 
useful for amniotic cell isolation. Tissues were obtained under appropriate Ethical Committee 
approval and signed informed consent (see appendix). All infectious pathogen–positive deliveries 
including those involving HBV, HCV, and HIV, as well as cases of prediagnosed genetic 
abnormalities, were excluded. Even with these precautions, standard precautions for safe use of 
human tissue must be followed. Placenta samples were procured immediately after delivery and 
kept in a sterile beaker. Once in the laboratory, placentas were transferred on a sterile field under 
flow laminar cabinet.  
 
3.1.1 Isolation of hAECs 
Reagents and solutions preparation (Miki et al, 2010): 
Pre-digestion buffer 
Prepare 1000 ml calcium- and magnesium-free HBSS (CMF-HBSS; Lonza, cat. no. 04-315Q) 
supplemented with 0.5 mM EGTA (Sigma, cat. no. E4378). Store up to 4 weeks at 4°C. 
Standard culture medium 
430 ml DMEM (Invitrogen, high-glucose formulation; cat. no. 11960044) 
5 ml 100 mM (100×) sodium pyruvate (Invitrogen, cat. no. 11360-070) 
50 ml heat-inactivated fetal bovine serum (Invitrogen, cat. no. 16141; 10% v/v final) 
5 ml 100 mM (100×) nonessential amino acids (Invitrogen, cat. no. 11140-050) 
5 ml 200 mM L-glutamine (Cellgro, cat. no. 25-005-CI) 
500 μl 55 mM 2-mercaptoethanol (Invitrogen, cat. no. 21985-023) 
5 ml antibiotic-antimycotic solution (Cellgro, cat. no. 30-004-CI) 
10 ng/ml human recombinant epidermal growth factor (EGF; Sigma, cat. no. E9644) 
Store up to 15 days at 4°C 
In this standard culture medium the cells grow for 2 to 6 passages, a passage being approximately a 
1:3 split when the cells approach confluence. Removal of the EGF results in a rapid decrease in 
proliferation and what appears to be terminal differentiation. Even in the continued presence of 
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serum and EGF, the cells do not normally proliferate past passage 6 under the culture conditions 
described here. 
 
Carry out dissection: 
- Wearing sterile gloves, place the whole placenta on the sterile field (Fig.11).  
The maternal surface (rough surface) 
should be facing down on the paper, with 
the smooth surface bearing the umbilical 
cord facing up. In this position, the amnion 
membrane will lay across the upper surface 
of the placenta. 
 
 
 
 
 
- Trim the umbilical cord close to the placental surface and cut an X-shaped incision into, but 
not through, the placental tissue (Fig.12). The X 
should intersect at the position of the umbilical 
cord. It may be easiest to start the incision in the 
region of the umbilical cord. After this step there 
could be an excess of blood on top of the amnion. 
If that is the case, pour some CMF-HBSS on top 
of the membrane and gently massage to remove 
blood clots. 
 
 
 
- Peel the amnion membrane from the underlying chorion layer of the placenta body. Start 
from the cut edge (middle of the placenta body) and peel the membrane from the placenta. 
In order to avoid taking extra tissue, pinch the rough part with a second pair of forceps and 
only collect the amnion. This phenomenon is more common in tissue from lengthy labor or 
when the amnion is partially detached from the discoid placenta. 
Figure 12- placenta with an X-shaped incision 
Figure 11- Placenta with amnion membrane facing up 
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- Place the amnion in the sterilized 500-ml glass beaker containing 200 ml CMF-HBSS 
(Fig.13), discarding the remaining part of the placenta. 
- Wash the amnion two to three times, 
each time by moving the amnion to a 
clean 500-ml beaker containing 200 ml 
fresh CMF-HBSS. This washing step is 
crucial for the trypsin to work properly. 
Blood clots will reduce the efficiency of 
the trypsin. Ideally, all clots on the 
membrane will be cleared. 
 
 
Digest the membrane 
- Thaw and prewarm the trypsin/EDTA solution to 37°C in a water bath. 
- Place the membrane in a 50-ml centrifuge tube and add 20 ml pre-digestion buffer. Gently 
rock the membrane in the solution for 30 sec, then transfer the membrane with forceps to 
two new 50-ml tubes. Discard the buffer. 
- Add 20 ml of pre-digestion buffer to the tissue in the tubes. Incubate 10 min at 37°C. 
- Transfer the membrane into new tubes (discarding the pre-digestion buffer) and add 30 ml 
trypsin/EDTA solution. Incubate for 40 min at 37°C. Save the trypsin digest. 
- Transfer the membrane into new 50-ml tubes, add 30 ml fresh trypsin/EDTA, and incubate 
for an additional 40 min. Save the trypsin digest. 
- Add two volumes of standard culture medium to both the two trypsin digests and centrifuge 
10 min at 200 × g, 4°C. 
- Decant the supernatant and resuspend the pellet in appropriate volume of standard culture 
medium. The cell pellet might appear like a compact tissue-like aggregate. Pipet up and 
down several times in order to release the cells. Discard any remaining small cell aggregate 
or filter the cell preparation through a 100-μm filter. If necessary, centrifuge one or two 
more times at 200 × g, 4°C. 
Prepare cultures 
- Count the cell number. 
- If cells are to be cultured, plate up to 1 × 105 cells per cm2 in standard culture medium. 
 
Figure 13- Washing the amniotic membrane in 
HBSS 
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3.1.2 Isolation of hAMSCs 
Reagents and solutions preparation (Marongiu et al, 2010): 
Digestion solution 
500 ml EMEM (with 25mM HEPES buffer without L-glutamine, with Earle‟s BSS; Lonza, cat. no. 
12-136F) supplemented with: 
1 mg/ml Collagenase type IV (Sigma, cat. no. C5138) 
25 μg/ml DNase I (Sigma, cat. no. DN25) 
To be prepared fresh in a volume proportional to the amount of tissue. 
Standard culture medium 
430 ml DMEM (Lonza, cat. no. 12-604F, with 4.5 g of glucose/liter) 
5 ml sodium pyruvate (Invitrogen, cat. no. 11360-070) 
50 ml 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen, cat. no. 16141) 
5 ml 100 mM non-essential amino acid (Invitrogen, cat. no. 11140-050) 
5 ml 200 mM L-glutamine (Cellgro, cat. no. 25-005-CI) 
500 μl 55 mM 2-mercaptoethanol (Invitrogen, cat. no. 21985-023) 
5 ml antibiotics solution (Cellgro, cat. no. 30-004-CI) 
10 ng/ml epidermal growth factor (EGF; Sigma, cat. no. E9644, human recombinant) 
Store up to 2 weeks at 4°C 
The isolation of hAMSCs is performed after the isolation of hAECs as follows: 
- Transfer the membrane into a 500-ml beaker with cold HBSS. 
- Wash the amnion two to three times with 200 ml HBSS, each time by moving the amnion to 
a clean beaker. 
Digest the membrane 
- Transfer the membrane into two (or more) 50-ml centrifuge tubes, allowing excess HBSS to 
drip from the membrane. The amount of wet tissue will be increased after trypsin digestion. 
In order not to dilute the collagenase solution excessively, divide the tissue as needed so as 
not to have more than 20 ml of wet tissue in 50 ml final volume. 
- Add the digestion solution to completely fill the tubes. Incubate on a rotator 1 hr at 37°C. 
- The incubation time varies according to the membrane thickness, ranging between 45 min to 
1.5 hr. It is wise to occasionally check the status of digestion after the first 30 min, and stop 
the incubation as soon as the tissue is completely dissolved. 
- Equally divide the contents of each tube into two new 50-ml tubes. 
- Add an equal volume of cold HBSS and centrifuge 5 min at 200 × g, 4°C. 
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- Discard the supernatant. Resuspend the pellet with fresh HBSS to fill the tube and centrifuge 
again 5 min at 200 × g, 4°C. 
- Resuspend the pellets in a small volume of standard culture medium and combine them in a 
single solution. 
- Count the cell number. 
- If cells are to be cultured, plate up to 1 × 105 cells per cm2 in standard culture medium. 
 
3.1.3 Purification of amniotic mesenchymal stromal cells from amniotic epithelial cells 
Although the isolation of hAECs by trypsin/EDTA digestion yields a virtually pure preparation, this 
is not the case for hAMSCs isolation; a considerable number of hAECs may still be attached to the 
membrane before collagenase digestion, and this may result in the presence of hAECs in the 
hAMSCs preparation. 
Considering the slow adhesion of hAECs to culture substrates, as opposed to the fast attachment of 
hAMSCs, it is good practice to change the culture medium 1 to 2 hr after plating. This will remove 
many of the hAECs that might be present in the preparation. However, significant contamination of 
hAMSCs with hAECs will frequently occur. The morphological differences between the two cell 
types will allow to easily determine whether the contamination with hAECs is substantial or not 
after 24 hr in culture.  
 
3.1.4 Determination of cell counts 
Cell counts were routinely determined prior to seeding cells into fresh media. After harvesting and 
re-suspending, 10 μl aliquots of cells were placed in the chambers of a hematocytometer. Cells in 
each corner quadrant of the grid were counted and multiplied by 10
4
 to give the number of cells per 
ml since the area of the 4 corner squares is 1 mm
3
 (0.1 mm
3
 x 10
4
 = 1 ml). Volumes of cells were 
then adjusted to give the desired seeding densities. 
 
3.1.5 Cryopreservation of cells 
The cells harvested were cryopreserved re-suspending the pellet in cold 10% dimethyl sulphoxide 
(DMSO, diluted in 1ml of the desired media). Cell suspensions were placed in a sterile cryovial and 
immediately stored at -80°C for freezing for four hours then transferred to liquid nitrogen (-179°C).
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3.2 Characterization of human Amniotic Epithelial and Mesenchymal Stromal Cells 
3.2.1 Flow cytometry 
Flow cytometric analyses of hAECs and hAMSCs were performed at different passages. 
Cultured cells were characterized by means of flow cytometry for membrane antigens. Cells were 
detached from culture flask using trypsin and, after washing, were incubated with 4% normal mouse 
serum/PBS/NaN3 for 20 minutes at 4°C in order to block non-specific Fc receptor sites on cell 
membrane. Cells were then stained in the dark at 4°C for 20 minutes with 7-amino actinomycin-D 
to discriminate viable cells from fragments and dead cells and with monoclonal antibodies conjugated 
with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) or PE-Cyanin 7 (PE-Cy7) or 
allophycocyanin (APC) or APC-Cyanin 7 (APC-Cy7). The cells were characterised at different 
passages using the following monoclonal antibodies (moabs): anti-epithelial cell adhesion molecule 
(EpCAM), anti-Thy-1, anti-ATP binding cassette-G2 (ABCG2), anti-CD45, anti-CD34, anti-CD44, 
anti-CD49f, anti-CD56 (Neural Cell Adhesion Molecule, NCAM), anti-CD13, anti-CD166 
(Leukocyte Cell Adhesion Molecule, LCAM), anti-CD146,  anti-CD105, anti-CD29, anti-CD73, 
anti-CD31, anti-SSEA4 (Becton Dickinson Biosciences, BD, Franklin Lakes, NJ, USA), anti-
CD133-1 (Miltenyi Biotech, Bergisch Gladbach, Germany).  
For internal labeling, cells were fixed at room temperature with 4% paraformaldehyde (PFA) for 10 
min and permeated with 100% ethanol for 2 min after washing with PBS. Cells were incubated with 
10% FBS to block non-specific binding, followed by primary antibody Oct-4 and Nanog (Santa 
Cruz Biotechnology, Inc. USA) for 1 hour; secondary FITC-conjugated antibody (Molecular 
Probes) was applied for 30 min. Mouse or rat non-immune immunoglobulins were always used as 
controls. The fluorescence threshold between negative and positive cells was set on the basis of the 
reactivity of appropriate non-specific fluorochrome-conjugated isotypical controls. No lysing or 
fixing procedures were applied to cell suspensions to avoid possible changes on antigen expression 
and cellular alterations. At least 10
6
 cells were finally analysed using a FACSCanto II equipped 
with FACSDiva software (BD). 
 
3.2.2 Immunofluorescence Microscopy of Cultured Cells 
Fixed plated cells (4% paraformaldehyde or 70% ethanol) were permeabilized and then 
immunostained with anti-EpCAM, anti-cytokeratin (CK)-18, anti-alpha-foetoprotein (Sigma), anti-
CK19 (Novocastra, Newcastel, UK), anti-albmin (Dako-Cytomation, Milan, Italy), anti-CK7, anti-
CD49f, anti-CD29, anti-S100A4, anti-CD90, anti-CD31, anti-CD146, anti-ZO-1, anti-fibronectin, 
anti-alpha1-antitrypsin, anti-E-cadherin, and anti-Beta-catenin (BD). 
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The following procedure was applied: 
- Wash the plated cells three times in PBS; 
- Fix the plated cells in 4% paraformaldehyde or 70% ethanol for 30 min.; 
- Wash the cells twice in PBS; 
- Permeabilize using HEPES-Triton X-100 buffer 0.25% in PBS; 
- Wash the cells twice in PBS; 
- Incubated with a permeabilisation Horse (or Horse-Goat) Serum Dilution Buffer containing 
0.5 M NaCl, 20 mM NaHPO4, 0.1% Triton X-100 and 30% horse (or horse and goat) serum 
for 30 min.;  
- Wash the cells several times in PBS; 
- Add the primary antibodies diluted in PBS and incubate for 2 h at room temperature;  
- Wash the cells several times in PBS;  
- Add fluorescence-conjugated specific secondary antibodies and incubate for 1 h at RT in a 
dark room; 
- Wash the cells several times in PBS; 
- Stain the cell nuclei with 4‟- 6‟-diamidino-2-phenylindone DAPI (Sigma) for 5 min. in a 
dark room; 
- Wash the cells several times in PBS. 
Images were taken using a Leica Microsystems DM IRE 2 microscope and analysed with the 
FW4000I software (Leica Microsystems, Milan, Italy). 
 
3.2.3 Cytogenetic analysis 
Chromosome analysis of amniotic epithelial and mesenchymal cells at different passages were 
performed.  
- After removing culture medium, add 3 ml of hypotonic solution (0.6 g  trisodium citrate and  
0.15 g  KCl in 100 ml distilled water) and incubate 10 minutes at room temperature. 
- Remove hypotonic solution and add 3 ml Ibraimov solution (acqueous acetic acid 5%); 
incubate 5 minutes at room temperature. 
- Remove Ibraimov solution and add 3ml of fresh fixative (4:1 methanol - acetic acid). 
- Remove the fixative and add 3 ml of new fixative solution. 
- Remove the glass slide from the capsule, remove the excess of liquid and dry it in 
Optichrome at 28°C 42% humidity.  
MATERIALS AND METHODS: Cell differentiation 
 
 
 
42 
The cells on the slides were observed and analyzed with a fluorescence microscope Olympus BX 
41: mercury vapor lamp HBO 100 W high pressure, excitation filter 425-503 nm, barrier filter 415 
nm. The source is a mercury vapor lamp characterized by a linear characteristic spectrum, with high 
emission intensity in some spectral bands (ultraviolet, blue and green). 
The image analyzer is connected to the microscope for cytogenetics through a camera and the 
camera is connected to a digital processing system. The analyzer used in our laboratory is 
Cytovision ™ System, an analytical tool that assists the cytogeneticist in the observation of the 
metaphases of chromosomes and in detecting cell abnormalities. 
 
3.4 Cell differentiation 
Differentiation towards different lineages was investigated for both hAECs and hAMSCs.  
Bone marrow stem cells were used as positive control for differentiation; experiments were 
repeated with different samples. 
 
Adipogenic differentiation  
To induce adipogenic differentiation, 1 to 3 passages cells were plated at 4x10
3
 cells/cm
2
 density on 
tissue culture dishes (Falcon, BD) and treated with adipogenic medium for three weeks. Medium 
changes were carried out 3 times a week and adipogenisis was assessed at 21 days. Adipogenic 
medium consisted of DMEM low glucose (Sigma) supplemented with 10% FBS (Gibco), 0.25mM 
IBMX (Sigma), 0.1μM dexamethasone (StemCell Technologies Inc.), 66nM insulin (MP 
Biomedicals, Germany), 1nM Triiodothyronine T3 (Sigma), 10μM rosiglitazone (Avandia®, 
GlaxoSmithKline, United Kingdom), 10mM hepes (Sigma), 170μM pantotenate, 33μM biotin (Ink 
Biomedicals, USA), 10μg/ml transferrin (MP Biomedicals), 1% penicillin/streptomycin and 1% L-
glutamine (Gibco). 
 
Osteogenic differentiation  
To induce osteogenic differentiation, 1 to 3 passages cells were plated at 4x10
3
 cells/cm
2
 density on 
tissue culture dishes (Falcon, BD) and treated with osteogenic medium for 3 weeks with medium 
changes 3 times a week. Osteogenesis was assessed at 21 days. Osteogenic medium consisted of 
DMEM low glucose (Gibco) supplemented with 100nM dexamethasone, 10mM β-glycerol 
phosphate, 50μM ascorbic acid 2 phosphate (StemCell Technologies Inc.), 1% 
penicillin/streptomycin (Gibco). 
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Hepatocyte differentiation 
A simple protocol for hepatic differentiation is shown in the schematic form in Fig.14. For hepatic 
differentiation, hAECs and hAMSCs were plated on 
type 1 collagen-coated culture dishes in standard 
culture media supplemented with neaa, glu, 2ME 
and EGF and steroid hormones such as 
hydrocortisone (HydC) or dexamethasone (Dex) 
(Miki et al, 2009).  
 
3.4.1 Airway epithelium differentiation  
To induce airway epithelium differentiation, the following protocol was applied (Karp et al, 2002). 
Reagents and solutions preparation: 
Airway medium 1: this medium is for cell seeding and the first culture day only. It is composed of a 
ratio of a 1:1 of DMEM and Hams F-12 supplemented with 5% FBS (not heat-inactivated) and 1% 
MEM non essential amino acids solution (Life technologies, cat. No. 11140-050) 
Airway medium 2: this medium is for use after culture d1 and then continuously. It consists of a 1:1 
ratio of DMEM and Hams F-12 supplemented with 2% Ultroser G. 
Permeable membrane support for culture epithelia: Costar Transwell-Clear, 0.4 um pore size, 
6.5mm diameter (Costar, Cat. No. 3470) (Fig. 15). 
 
 
Figure 15 – Plate with permeable supports 
 
 
Preparation of permeable membranes: 
Coat the membrane insert with a solution of human placental collagen (60 µg/ml) for a minimum of 
18 hours: 
Figure 14- Protocol for hepatic differentiation 
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- use a ratio of 30 mg collagen with 50 ml deionized water and 100 µl glacial acetic acid. 
- Cover the holding beaker with parafilm and stir moderately at about 37°C until collagen 
strands are dissolved. 
- Dilute the filtered collagen stock 1:10 with deionized sterile water. This diluted collagen 
stock is the working solution (60 µg/ml) for coating plastic and membrane surfaces.  
- Filter sterilize with a 0.2 µm membrane. If the filter membrane quickly plugs, the collagen 
strands have not fully dissolved. 
- Collagen-coat the surface of membrane for a minimum of 18 hours at room temperature. 
The collagen improves cell attachment efficiency and proliferation. 
- On the day of cell seeding remove the liquid collagen from surface and air-dry the 
membrane surface. 
- Rinse at least twice with sterile PBS on both side of membrane support. It is important to 
remove all trace of the liquid collagen. Residual liquid collagen can be toxic to cells. 
Seed the cells 
- the seeding range should be 2.5x105 to 5x105 cells/cm2. 
- The cell suspension seeded onto the top of the permeable membrane insert should be of 
sufficient volume, 100-400 µl, to insure a uniform distribution of cells settling upon the 
membrane surface. The volume of the medium under the membrane insert should be 
sufficient (250-500 µl) to immerse the membrane bottom without floating the insert. 
- After seeding, make sure that the membrane supports are level to insure uniform cell 
attachment during the first 12 hours.  
- Leave the cluster dishes with the seeded membrane supports undisturbed for a minimum 18-
24 hours in a CO2 incubator at 37°C and 8 to 9% CO2. The higher CO2 increases successful 
achievement of confluence. 
- The day after seeding, change the airway medium 1 on both sides of the membrane to 
airway medium 2 (2% Ultroser G). 
- Remove the top medium with vacuum suction and rinse the top membrane surface once with 
airway medium 2 to remove unattached cells (Fig. 16). 
- Then remove the medium from the top of the membrane surface (air interfacing) so that 
medium is present only on the bottom of the membrane insert. When cells grow at the air 
interface, they form a confluent sheet with tight junctions and no visible fluid on top. The air 
interface allows the confluent sheet to better differentiate as a barrier separating air on top 
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from the liquid media immersing the bottom. This air interface condition is comparable to 
the air-covered surface of the airway epithelium in vivo. 
 
Figure 16 – hAECs and hAMSCs were cultured in vitro on microporous polyester membranes in submerged culture 
using airway medium 1 for the first day of culture after which they were raised to air liquid interface (ALI) for a further 
15-20 days to differentiate (right). 
 
 
- Remove any liquid form the top surface once daily until the membrane culture remains 
visibly dry on top, which usually occurs 3-6 days after seeding in 8 to 9% CO2. 
- Maintain the airway medium 2 on the bottom side of the membrane insert for the entire 
culture duration to prevent the culture form drying and the cells dying. 
- After the cells achieve the confluence, the polarized sheet of cells will regulate the minimal 
fluid level and content on top. The amount of liquid is so small that is not visible to the eye. 
- After the first 4-6 days of culture and once the air interface can be maintained by the cells, 
keep the culture in a 5%CO2 humidified atmosphere at 37°C. 
- Remove any liquid on the top surface daily, until the epithelium becomes confluent and can 
maintain the air interface. 
 
3.4.2 Stem cell labelling 
hAECs and hAMSCs were labelled with Chloromethylbenzamido (CellTrackerTM CM-DiI) (Fig. 
17). CM-DiI incorporates a mildly thiol-reactive chloromethyl substituent that confers aldehyde 
fixability via conjugation to thiol-containing peptides and proteins. 
Stock solutions of CM-DiI were prepared in dimethylsulfoxide (DMSO) at 1 ng/μl. Immediately 
before labeling, the stock solution was diluted up to a final concentration of 0.005 ng/μl into 
Dulbecco Modified Eagle‟s Medium (DMEM) without phenol red. Cells grown at confluency in a 
T25 flask were washed with phosphate-buffered saline (PBS) and then incubated with the dye 
working solution for 30 minutes at 37°C. After labelling, cells were washed twice with PBS, then 
incubated at 37°C  5% CO2 for at least 24h in the presence of fresh medium (Fig. 18).  
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Figure 17: Chemical structure of CellTrackerTM CM-DiI. 
 
 
Figure 18: hAMSCs labelled with CM-DiI after isolation. 
 
3.4.3 Co-culture of hAMSC with CFBE41o- 
Labelled hAMSCs were mixed with CFBE41o- (cystic fibrosis  human epithelial bronchial cell 
line) homozygous for the F508del allele (F508del/F508del), (generous gift of Professor D. 
Gruenert, University of California at San Francisco, USA) at different ratios (1:5 , 1:10, 1:15, 1:20) 
and,  in order to obtain  polarized co-cultures, cells were seeded on 6.5-mm diameter Snapwell, 0.4-
μm pore size (Corning, Acton, MA, USA) at 1 X 105 per filter coated with a solution of 10 μg/ml 
Fibronectin (BD Biosciences, CA, USA), 100 μg/ml albumin from bovine serum (Sigma-Aldrich, 
Milan, Italy), and 30 μg/ml bovine collagen type I (BD Biosciences) dissolved in Mimimum 
Essential Medium (MEM). Co-cultures were maintained at 37°C 5% CO2  at least for six days in 
order to obtain polarization.  
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3.5 Cell differentiation analyses 
Oil-Red-O staining. The presence of adipose elements in induced and control cultures was 
determined by Oil-Red-O staining (Sigma). The cells were washed in PBS, then fixed in 10% 
formalin for 1 hour, washed in isopropanol 60% and air-dried. The cells were incubated with Oil-
Red-O staining solution for 10 minutes, then washed several times in PBS. 
Alizarin Red staining. The presence of calcium deposits in induced and control cultures was 
determined by Alizarin Red at 2% in water at pH 4.2. The cells were fixed in 10% formalin for 1 
hour, then washed in deionized water and incubated for 30 min at room temperature with Alizarin 
Red. The cells were finally washed several times to remove the excess of staining.  
Evaluation of cytochrome P450 dependent mixed function oxidases. One of the functions in cultured 
hepatocytes is that of the cytochrome P450 dependent mixed function oxidases (MFO). Diethoxy 
(5,6) chloromethylfluorescein is a probe suitable for use as an in situ stain for MFO activity. It is 
postulated that the ethoxy groups are removed by MFO activity, and the chloromethyl moiety reacts 
with reduced glutathione to form the fluorescent conjugate which is retained within the cell 
(Anderson et al, 1998). The presence of cytochrome P450 in induced and control cultures was 
determined by specific probe hybridization and visualized by fluorescence microscopy.  
5mg of probe was eluted in 1143µl DMSO (Stock solution 10 mmol). Test medium was prepared as 
follow: 987µl di RPMI, 12µl HEPES 1M (12 mmol final), and 1µl probe 10 mmol (10 µmol final). 
Control medium was prepared as follow: 987µl RPMI, 12µl HEPES 1M (12 mmol final), and 1µl 
DMSO. The cells were washed in PBS and incubated with the test (or control) medium for 2 hours 
at 37°C in a dark room. Viable cells incorporate the probe and they metabolize it in a green 
fluorescent compound. The fluorescent compound can be visualized by fluorescence microscopy. 
 
3.5.1 Differentiation into airway epithelium 
3.5.1.1 Transepithelial resistance  
The evaluation of the polarized cultures is critically important to determine that they have the 
phenotype associated with airway epithelia. This can be done by routinely check the transepithelial 
resistance and morphology. 
Transepithelial resistance (TER) can be monitored using a portable voltohmmeter attached to dual 
“chopstick” electrodes (Fig. 19). Each of the two electrode stem contains at their tip a Ag/Ag Cl- 
electrode for measuring voltage and a concentric spiral of silver wire for passing current across 
epithelium. 
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TER was measured by the following steps: 
- Sterilize the electrode tips in 70% alcohol before use. 
- In order to measure electrical properties, place 300-400 l of medium on the apical surface. 
It is removed after measurement. 
 
Figure 19 – Voltohmmeter with “chopstick” electrodes. 
 
- Place the shorter electrode tip into medium on top of the apical surface and place the longer 
electrode tip into the external bathing medium. 
- TER values higher than the background fluid resistance indicate a confluent airway 
epithelium with tight junctions. 
 
3.5.1.2 Transepithelial Fluid Transport Measurement 
To quantify fluid absorption, the cells were cultured as explained above. Six days after seeding, the 
apical surface of epithelia was washed with a saline solution containing (in mM): 137 NaCl, 2.7 
KCl, 8.1 Na2HPO4, 1.5 KH2PO4, 1 CaCl2, 0.5 MgCl2, with or without 100 μM amiloride. The apical 
medium was removed, then 500 μl of room temperature saline solution was added to the apical 
surface. Filters were rotated gently to remove the medium remaining at the walls of the cup, and 
then the fluid was recovered and eliminated. This process was repeated three times. After washing, 
the apical side of the epithelium was covered with 50 μl of the same solution and 150 μl of mineral 
oil to prevent evaporation. Cells were maintained at 37°C in 5% CO2. After 24 hours, the apical 
fluid was carefully removed, centrifuged to separate the mineral oil, and the residual volume of 
aqueous phase measured. 
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3.5.1.3 CFTR cytofluorimetric assay 
 
Co-coltures of hAMSCs with CFBE41o- (at different ratios) were first detached with trypsin-EDTA 
treatment and fixed in PBS containing 2% paraformaldehyde for 5 min. After centrifugation at 1500 
rpm the resulting pellets were washed and resuspended in PBS. The cells were then incubated  with 
CFTR antibody  MAB25031 mouse IgG2a (R&D Systems, Minneapolis, MN)  used at 1:20 dilution 
for 1h at 4°C. After wash in PBS, the cells were incubated with the FITC-conjugated secondary 
antibody (anti mouse used at 1:100; Sigma) for 1h at 4°C, followed by  two washes in PBS, and 
analyzed by flow cytofluorimetry. Data were collected using a Coulter Epix XL flow cytometer 
(Beckman Coulter, Fullerton, CA) and analyzed with WinMDI 2.9 
(www.cyto.purdue.edu/flowcyt/software/Winmdi.htm). Ten thousand cells were examined in each 
experiment. Analysis was performed by plotting the FLH-1 channel (525 nm) against the FLH-2 
channel (575 nm). 
 
3.5.1.4 Confocal analysis  
       3.5.1.4.1 ZO-1 Immunodetection  
Polarized cells were washed three times with PBS, fixed in 3% paraformaldehyde, 2% sucrose for 5 
minutes at room temperature, and permeabilized with ice cold Triton Hepes buffer (20 mM Hepes, 
300 mM sucrose, 50 mM NaCl, 3 mM MgCl2, 0.5% Triton X-100, pH 7.4) for 5 min at room 
temperature. Cells were washed three times with BSA 0,2% in PBS and then incubated with 
blocking solution (2% BSA, 2% FBS in PBS), for 15 min at 37°C. Cells were then incubated with 
FITC-conjugated mouse anti-ZO-1 antibody in PBS 0.2 % BSA (Zymed Laboratories Inc., San 
Francisco, CA, USA) (dilution 1:50) for 30 min at 37°C, and finally were rinsed three times with 
0.2% BSA in PBS. Filters were excised and placed side up on a glass slide, and overlayed with a 
drop of Mowiol (Calbiochem, San Diego, CA, USA) followed by a coverslip. Cells were analyzed 
using Nikon TE2000 microscope coupled to a Radiance 2100 confocal dual-laser scanning 
microscopy system (Bio-Rad, Segrate, Italy). Specimens were viewed through a 60X oil immersion 
objective. Digital images were processed using the program Laser Sharp 2000 (Bio-Rad). 
 
       3.5.1.4.2 CFTR Immunodetection  
Polarized cells were washed three times with PBS, and incubated in PBS 2% BSA for 30 minutes 
on ice. Cells were incubated with CFTR antibody MAB25031 diluted 1:20 in PBS containing 0.2% 
BSA for 1h on ice. Cells were rinsed three times with PBS, and incubated with the FITC-
conjugated secondary antibody (Sigma) diluted 1:100 in PBS added with 0.2% BSA for 30 minutes
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 on ice. After two washes in PBS, cells were fixed in 3% paraformaldehyde, 2% sucrose for 10 
minutes. After three washes in PBS, filters were excised and placed side up on a glass slide, and 
overlayed with a drop of Mowiol followed by a coverslip. Cells were analyzed as described before 
for ZO-1. 
 
3.6 RNA extraction and RT-PCR 
Total RNA was isolated from undifferentiated and differentiated cells with TRIZOL® Reagent 
(Invitrogen), according to the manufacturer‟s protocol. 
The reagent is a mono-phasic solution of phenol and guanidine isothiocyanate. During sample 
homogenization or lysis, TRIZOL® Reagent maintains the integrity of the RNA, while disrupting 
cells and dissolving cell components. Addition of chloroform followed by centrifugation, separates 
the solution into an aqueous phase and an organic phase. RNA remains exclusively in the aqueous 
phase. After transfer of the aqueous phase, the RNA is recovered by precipitation with isopropyl 
alcohol. The RNA pellet is washed in Ethanol 70% in order to remove the impurities and then 
rehydrated with diethylpyrocarbonate (DEPC) water, which contains RNase inhibitors. All the 
following procedures must be performed in ice:        
- Lyse cells directly in a culture dish by adding 1 ml of TRIZOL® Reagent to a 3.5 cm 
diameter dish, and passing the cell lysate several times through a pipette. The amount of 
TRIZOL® Reagent added is based on the area of the culture dish (1 ml per 10 cm
2
) and not 
on the number of cells present. An insufficient amount of TRIZOL® Reagent may result in 
contamination of the isolated RNA with DNA. 
- Incubate the homogenized samples for 5 minutes at 15 to 30°C to permit the complete 
dissociation of nucleoprotein complexes. Add 0.2 ml of chloroform per 1 ml of TRIZOL® 
Reagent. Cap sample tubes securely.  
- Shake tubes vigorously by hand for 15 seconds and incubate them at 15 to 30°C for 2 to 3 
minutes.  
- Centrifuge the samples at no more than 12,000 × g for 15 minutes at 2 to 8°C. Following 
centrifugation, the mixture separates into a lower red, phenol-chloroform phase, an 
interphase, and a colorless upper aqueous phase. RNA remains exclusively in the aqueous 
phase. The volume of the aqueous phase is about 60% of the volume of TRIZOL® Reagent 
used for homogenization.  
- Transfer the aqueous phase to a fresh tube.  
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- Precipitate the RNA from the aqueous phase by mixing with isopropyl alcohol. Use 0.5 ml 
of isopropyl alcohol per 1 ml of TRIZOL® Reagent used for the initial homogenization.  
- Incubate samples for 10 minutes and centrifuge at no more than 12,000 × g for 10 minutes at 
2 to 8°C. The RNA precipitate, often invisible before centrifugation, forms a gel-like pellet 
on the side and bottom of the tube. 
- Remove the supernatant.  
- Wash the RNA pellet once with 75% ethanol, adding at least 1 ml of 75% ethanol per 1 ml 
of TRIZOL® Reagent used for the initial homogenization.  
- Mix the sample by vortexing and centrifuge at no more than 7,500 × g for 5 minutes at 2 to 
8°C. 
- At the end of the procedure, briefly dry the RNA pellet (air-dry or vacuum-dry for 5-10 
minutes). Do not dry the RNA by centrifugation under vacuum. It is important not to let the 
RNA pellet dry completely as this will greatly decrease its solubility. Partially dissolved 
RNA samples have an A260/280 ratio < 1.6. 
- Dissolve RNA in RNase-free water or DEPC water (0,01%) by passing the solution a few 
times through a pipette tip, and incubating for 10 minutes at 55 to 60°C.  
In order to verify purity and quantity, the absorbance of RNA at 260nm and 280nm was analysed by 
spectrophotometer and the RNA was evaluated on agarose gel. 
 
3.6.1 RT-PCR 
1μg of RNA was reverse-transcribed into first strand cDNA with the High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems) using random primers following manufacturer‟s 
instructions. 
 
- Prepare the reaction mix in ice: 
 
RT buffer 10X 2 µl 
dNTPs 100mM 0.8 µl 
Random primers 2 µl 
Multiscribe enzime 1 µl 
RNAse inhibitor 1 µl 
Sterile water 3.2 µl 
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- Aliquote the reaction mix into eppendorf tubes and add 5 µl RNA 200 ng/µl; 
- PCR reaction: 
 Step 1 Step 2 Step 3 Step 4 
Temperature (°C) 25 37 85 4 
Time 10‟ 120‟ 5‟‟ ∞ 
 
 
 3.6.2 cDNA processing 
3.6.2.1 α , β , γ ENaC expression 
In order to analyze the expression of  α, β, and γ ENaC subunits  by RT-PCR, 100 ng of  cDNA was 
added in a final volume of 25 l of reaction buffer containing 200 nM dNTPs, 10 pM of each 
primer (Table 1), 0.3 U Taq-DNA-polymerase, and MgCl2 (Invitrogen). Cycling conditions 
consisted of 1 cycle at 95°C for 6 minutes,  35 cycles consisting in denaturation at 95°C for 30 
seconds, annealing at 58°C for 1 minute and elongation at 72°C for 2 minutes, and 1 final cycle at 
72°C for 7 minutes.  
cDNA from H441 (human lung adenocarcinoma epithelial cell line) treated with dexamethasone 
were used as positive control for ENaC analysis. PCR products were evaluated on 1.5% agarose gel 
electrophoresis. 
 
3.6.2.2 CFTR expression 
In order to analyze the expression of CFTR gene, 100ng of cDNA was used in a final volume of 
25ul with 200nM dNTP, 10pM of each outer primer (Table 1), 0.3U Taq-DNA-polymerase, 
reaction buffer, and MgCl2 (Invitrogen). A second nested PCR was performed using inner primers 
(Table 1). Cycling conditions consisted of 95°C for 30 seconds, annealing at 60°C for 1 minute and 
elongation at 72°C for 2 minutes. Cycle numbers consisted of 35 cycles.  
cDNA from nasal brushing from healthy subject was used as positive control for CFTR analysis. 
Nested PCR products were evaluate on 1.5% agarose gel electrophoresis.  
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Gene 
Forward 
Primer 
Reverse 
Primer 
Product 
Lenght 
(bp) 
Alpha-ENaC CCTGGAATCAACAACGGTCT ATGTTGACTTTGGCCACTCC 614 
Beta-ENaC CCCCGTCCAAAACTTCTACA GATCTCCCCAAACTCGATGA 526 
Gamma- ENaC TCTACCTCCTGCAGCCAACT AAGCAGGCTTTTTGGTCAGA 845 
CFTR outer 
primers 
CGAGAGACCATGCAGAGGTC GCTCCAAGAGAGTCATACCA 1108 
CFTR inner 
primers 
CGAGAGACCATGCAGAGGTC TGTACTGCTTTGGTGACTTCCCC 301 
 
 
3.6.3 Real-Time PCR 
In conventional PCR, the amplification product is evaluate on agarose gel at the end of the reaction. 
On the contrary, real time PCR is a technique used to monitor the progress of a PCR reaction in real 
time. Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule 
which increases, as the reaction proceeds. The fluorescence emitted by the reporter molecule 
manifolds as the PCR product accumulates with each cycle of amplification. These fluorescent 
reporter molecules include dyes that bind to the double-stranded DNA (i.e. SYBR® Green ) or 
sequence specific probes (i.e. Molecular Beacons or TaqMan® Probes).  
Real time PCR facilitates the monitoring of the reaction as it progresses. One can start with minimal 
amounts of nucleic acid and quantify the end product accurately. Moreover, there is no need for the 
post PCR processing which saves the resources and the time. These advantages of the fluorescence 
based real time PCR technique have completely revolutionized the approach to PCR-based 
quantification of DNA and RNA. Real time PCR assays are now easy to perform, have high 
sensitivity, more specificity, and provide scope for automation.  
Real-Time PCR focuses on the exponential phase of PCR reaction because it provides the most 
precise and accurate data for quantitation. Within the exponential phase, the real-time PCR 
instrument calculates two values. The Threshold line is the level of detection at which a reaction 
reaches a fluorescent intensity above background. The PCR cycle at which the sample reaches this 
level is called the Cycle Threshold, Ct. The Ct value is used in downstream quantitation or 
presence/absence detection. By comparing the Ct values of samples of unknown concentration with 
a series of standards, the amount of template DNA in an unknown reaction can be accurately 
determined. 
Table 1 - Primer sequences for ENaC and CFTR analysis 
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Every real-time PCR reaction contains a fluorescent reporter molecule, a TaqMan® Probe, to 
monitor the accumulation of PCR product. As the quantity of target amplicon increases, so does the 
amount of fluorescence emitted from the fluorophore. 
TaqMan® Gene Expression Assays consist of a pair of unlabeled PCR primers and a TaqMan® 
probe with a FAM™ or VIC® dye label and minor groove binder (MGB) moiety on the 5' end, and 
non-fluorescent quencher (NFQ) dye on the 3' end. 
An oligonucleotide probe is constructed containing a reporter fluorescent dye on the 5' end and a 
quencher dye on the 3' end. While the probe is intact, the proximity of the quencher dye greatly 
reduces the fluorescence emitted by the reporter dye by fluorescence resonance energy transfer 
(FRET) through space. If the target sequence is present, the probe anneals downstream from one of 
the primer sites and is cleaved by the 5' nuclease activity of Taq DNA polymerase as this primer is 
extended. This cleavage of the probe:  
- Separates the reporter dye from the quencher dye, increasing the reporter dye signal.  
- Removes the probe from the target strand, allowing primer extension to continue to the end 
of the template strand. Thus, inclusion of the probe does not inhibit the overall PCR process.  
Additional reporter dye molecules are cleaved from their respective probes with each cycle, 
resulting in an increase in fluorescence intensity proportional to the amount of amplicon produced. 
When calculating the results of real-time PCR experiment, it can be used either absolute or relative 
quantitation. In absolute quantitation, unknowns are quantitated based on a known quantity, through 
the creation of a standard curve. In relative quantitation, changes in gene expression in a given 
sample relative to another reference sample (such as an untreated control sample) are analyzed. 
The comparative Ct method compares the Ct value of one target gene to another (using the formula: 
2
ΔΔCT
) - for example, an internal control or reference gene (e.g., housekeeping gene) - in a single 
sample. For the comparative Ct method to be valid, the efficiency of the target amplification (your 
gene of interest) and the efficiency of the reference amplification (your endogenous control) must 
be approximately equal. 
In the present study, the following TaqMan probes have been used: 
- Hs02387400_g1 (NANOG), a transcription factor critically involved with self-renewal of 
undifferentiated embryonic stem cells. NANOG is a gene expressed in embryonic stem cells 
(ESCs) and is thought to be a key factor in maintaining pluripotency. NANOG is thought to 
function in concert with other factors such as POU5F1 and SOX2 to establish ESC identity. 
These cells offer an important area of study because of their ability to maintain 
pluripotency.  
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- Hs00360675_m1 (SALL4), a gene part of a group of genes called the SALL family. These 
genes provide instructions for making proteins that are involved in the formation of tissues 
and organs during embryonic development. SALL proteins are transcription factors, whose 
exact function remains unclear. Based on the functions of similar proteins in other 
organisms (such as zebrafish and mice), the SALL4 protein appears to play a critical role in 
the developing limbs. This protein may also be important for the development of nerves that 
control eye movement and for the formation of the walls (septa) that divide the heart into 
separate chambers. 
- Hs00195591_m1 (SNAI1). The Drosophila embryonic protein snail is a zinc finger 
transcriptional repressor which downregulates the expression of ectodermal genes within 
the mesoderm. The nuclear protein encoded by this gene is structurally similar to the 
Drosophila snail protein, and is also thought to be critical for mesoderm formation in the 
developing embryo. At least two variants of a similar processed pseudogene have been 
found on chromosome 2. 
- Hs99999909_m1 (HPRT) used as reference. The HPRT1 gene provides instructions for 
producing an enzyme called hypoxanthine phosphoribosyltransferase 1. This enzyme allows 
cells to recycle purines, a type of building block of DNA and its chemical cousin RNA. 
Manufacturing purines uses more energy and takes more time than recycling purines, which 
makes recycling these molecules more efficient. Recycling purines ensures that cells have a 
plentiful supply of building blocks for the production of DNA and RNA. The process of 
recycling purines is also known as the purine salvage pathway. 
  
PCR reaction was performed as follow: 
 TEMPERATURE 
(°C) 
TIME 
NUMBER OF 
CYCLES 
Enzyme activation  
50 
95 
2‟ 
10‟ 
1 
Denaturation, 
annealing and 
extension 
90 
60 
15‟‟ 
1‟ 
40 
 
RESULTS 
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4. RESULTS 
 
4.1 Isolation and characterization of cells from human amnion 
The collection of human term placentas after birth was carried out in the Department of 
Gynaecology and Obstetrics of Fondazione IRCCS Ca‟ Granda Ospedale Maggiore Policlinico of 
Milan, after obtaining informed consent from the mother. Through mechanical separation and 
successive enzymatic digestions, two cellular fractions from the amnion were isolated: human 
amniotic epithelial cells (hAECs), and amniotic mesenchymal stromal cells (hAMSCs). 
At least 65 x 10
6
 hAECs (range: 6-130 x 10
6
) were recovered in each isolation with a viability of 
75-85%.  
At least 33 x 10
6
 hAMSCs (range 26-160 x 10
6
) were recovered in each isolation with a viability of 
85-90%.  
 
4.1.1 Morphology 
In the presence of EGF, hAECs proliferated robustly and formed a confluent monolayer of 
cobblestone-shaped epithelial cells (Fig. 20A and 20B). 
The mesodermal fraction of the amnion (hAMSCs) was characterized after plastic adhesion by a 
fibroblastic morphology very similar to that described for mesenchymal cells isolated from bone 
marrow (Fig. 20C and 20D). 
 
4.1.2 Growth kinetics 
Isolated hAECs readily attached to plastic or basement membrane-coated culture dishes and could 
be kept until six passages before proliferation ceased. Approximately one cell doubling was 
observed over 15 days, giving these cells an average doubling time of 20.35 in the presence of EGF. 
Without EGF, the proliferation stopped early and giant multinuclear cells were formed. If cells were 
cultured in low densities, the senescence occurred before, apparently due to less cellular interaction 
and complex molecular steps related to EGF receptor and integrins. 
hAMSCs adhered and proliferated on tissue culture plastic and could be kept until passages 5-10. 
Proliferation slowed beyond passage two. Approximately two cell doublings were observed over 15 
days, giving these cells an average doubling time of 18.03. 
Growth curves for hAECs and hAMSCs are presented in Figure 21. 
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A C
B D
 
Figure 20 –Culture of placenta derived stem cell types (phase contrast micrograph pictures); magnification ×10. 
A) hAECs passage 1; B) hAECs passage 3; C) hAMSCs passage 1; D) hAMSCs passage 3 
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Figure 21 – Growth kinetics of hAEC (blue) and hAMSC (pink) 
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4.1.3 Flow cytometry analysis 
Although the hAEC had a homogeneous morphology appearance, the isolated cells showed a 
heterogeneous phenotype, suggesting that might be different subpopulations of cells. The hAECs 
showed antigens such as the EpCAM, CD49F, CD29, CD73, CD166 (Table 2). They did not 
express CD34 (marker of hematopoietic and endothelial stem cells) and CD45 (pan leukocyte 
marker), nor CD133 (expressed in hematopoietic stem cells, endothelial cells, glioblastoma cells). 
They did not show mesenchymal markers as CD105, at least in the first passages, while the 
expression of CD90 (Thy-1) was stable during culture. 
The hAMSCs showed surface marker associated with mesenchymal cells form bone marrow as 
CD105, CD73 and CD90. They do not express hematopoietic markers (CD34 and CD45). Fresh 
isolated hAMSC showed relatively low expression of epithelial markers (EpCAM and 49F), which 
decreased after the first passage (Table 3). Since these markers were expressed by a separate 
population, we hypothesized a possible epithelium contamination.  
Representative flow analysis diagrams of hAECs and hAMSCs are shown in Figure 22.  
hAECs and hAMSCs showed surface markers associated with embryonic stem cells such as SSEA4 
(stage specific surface embryonic antigen 4), while no expression by flow cytometry of molecular 
markers associated to pluripotent stem cells (Nanog, Oct-4) was observed (Fig. 23). 
 
4.1.4 Immunofluorescence analysis 
Immunohystochemistry stains showed that virtually all cultured hAECs were positive to low 
molecular weight cytokeratin, EpCAM, Beta-catenin, E-chaderin, ZO-1 and alpha1-anti trypsin. 
The amniotic epithelial cells expressed not only epidermal markers and general epithelial markers, 
but also expressed vimentin. (Fig. 24A, 24B and 24C).  
Human amniotic mesenchymal cells (hAMSCs) were positive for CD90, CD29, fibronectin and 
vimentin (Fig. 24A, 24B and 24C).  
These facts suggested that the amnion derived cells had not completely differentiated into epithelial 
or mesenchymal cells. Another explanation from the embryological point of view is that the 
epithelial-mesenchymal transition (EMT) may occur in the amniotic membrane.  
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Table 2 – Phenotypic characterization of hAECs at passage 1and 3 by flow cytometry 
 PASSAGE 1 PASSAGE 3 
Surface antigens 
 
Median % 
(n=6) 
Range 
 
Median % 
(n=6) 
Range 
 
CD 90 42 27-95 46 12-59 
ABCG2 0 0-1 0 0-3 
CD 34 1 0-7 2 0-10 
CD133 0 0-1 0 0-2 
EpCAM 94 78-100 93 92-95 
CD 166 100 77-100 99 94-100 
CD 44 39 13-78 60 29-99 
CD 49f 98 91-99 100 95-100 
CD 29 97 95-100 100 98-100 
CD 105 4 0-52 38 3-52 
CD 73 100 95-100 100 97-100 
CD 31 2 0-7 2 0-4 
CD146 1 0-1 3 1-5 
CD 13 12 2-24 2 1-4 
CD 45 0 0-5 2 1-2 
 
 
 
Table 3 – Phenotypic characterization of hAMSCs freshly isolated and at passage 2 by flow 
cytometry 
 
FRESHLY 
ISOLATED 
PASSAGE 2 
Surface antigens 
Median % 
(n=3) 
Range 
Median 
(n=3) 
Range 
CD105 49 30-66 58.4 40-76 
CD90 79 69-89 94.1 89-99 
CD34 0 0-1 0.5 0-1 
CD133 0 0-1 0.5 0-1 
EpCAM 16 12-10 0.3 0-1 
CD166 83 71-95 84.8 71-98 
CD44 81 71-90 90.3 89-92 
CD49f 16 13-31 2.5 2-5 
CD73 90 88-91 93.7 88-99 
CD31 0 0 ND  
CD146 0 0 ND  
CD13 80 70-89 94.6 89-99 
CD45 2 0-4 4.3 3-4 
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Figure 22 – Representative flow analysis diagrams of hAECs (green lines) and hAMSCs (red lines). The percentage of 
the positive fraction is relative to isotype controls.  
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Figure 23 – Fluorescence-activated cell sorting analysis for molecular markers of pluripotent stem cells (Nanog and 
Oct-4) and surface marker of embryonic stem cells (SSEA4) for hAECs and hAMSCs. 
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Figure 64A - Immunohystochemistry stains for hAECs and hAMSCs.  
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Figure 24B - Immunohystochemistry stains for hAECs and hAMSCs. 
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Figure 24C – Immunohystochemistry stains for hAECs and hAMSCs. 
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4.1.5 Cytogenetic analysis 
Karyotypes were normal 46, XX or 46, XY (Fig.25) in all test samples and the analyses revealed no 
variation at different passages. Karyotype analyses confirmed the fetal origin of both hAECs and 
hAMSCs. 
 
 
 
Figure 25 - All cell lines displayed normal karyotype: hAECs (passage 1), hAMSCs (passage 2). 
 
 
 
 
 
 
 
 
 
hAMSC 46, XY 
hAEC 46,  XX 
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4.1.6 Real time PCR 
RNA extracted from cells was quantified by biophotometer and visualized on agarose gel 
electrophoresis (Fig. 26). A mean of 370 ng/µl RNA was extracted for each sample, with a purity 
(Absorbance 260/280) higher than 1.98. 
 
 Real time PCR was executed on RNA samples extracted from 
cultured amniotic cells at different passages. RNA from Embryonic 
Stem Cells (generous gift of Prof. E. Cattaneo, University of 
Milan) was used as positive control; RNA from human 
lymphocytes was used as negative control. 
Real time PCR was performed in order to verify the mRNA 
expression of NANOG, SALL4 and SNAI1. HPRT was used as 
housekeeping gene. 
At mRNA level, both hAECs and hAMSCs showed NANOG 
expression, a transcription factor critically involved with self-
renewal of undifferentiated embryonic stem cells (Fig.27A), even 
if at lower levels than ES. Interestingly, the expression of this gene in hAECs decreased during the 
passages, while in hAMSCs the expression remained stable.  
The expression of SALL4, a gene involved in the formation of tissues and organs during embryonic 
development, appeared to be significantly lower than that of ES. We observed a slight increase of 
the expression of this gene during the culture of hAMSC (Fig.27B) 
The expression of SNAI1, transcriptional repressor which downregulates the expression of 
ectodermal genes within the mesoderm appeared to be obviously stable in hAMSCs. In hAECs, we 
observed an increase in SNAI1 expression during the passages, probably do to epithelial-
mesenchymal transition that may occur in the amniotic membrane (Fig.27C). 
Data were confirmed by different experiments. 
 
 
Figure 26 - Visualization on 
agarose gel electrophoresis of RNA 
samples extracted from cells. Most 
abundant RNA species are 28S and 
18S. 
28S
18S
RESULTS: Isolation and characterization of cells from human amnion 
 
 
 
68 
after rescaling (log scale)
0.010
0.100
1.000
10.000
1 2 3 4 5 6 7 8
SNAI1
Sample ID Sample Expression level SD 
1 hAEC T0 0.114 0.072 
2 hAEC P1 0.164 0.045 
3 hAEC P3 0.350 0.164 
4 hAMSC T0 1.107 0.121 
5 hAMSC 1P 1.421 0.166 
6 hAMSC 3P 1.000 0.195 
7 ES 0.283 0.054 
8 Neg CTR 0.094 0.017 
 
SNAI1
after rescaling (log scale)
0.100
1.000
10.000
100.000
1000.000
1 2 3 4 5 6 7 8
NANOG
NANOG
Sample ID Sample Expression level SD 
1 hAEC T0 21.187 2.488 
2 hAEC P1 3.522 0.276 
3 hAEC P3 2.195 0.304 
4 hAMSC T0 0.668 0.055 
5 hAMSC 1P 1.306 0.196 
6 hAMSC 3P 1.000 0.285 
7 ES 307.114 32.706 
8 Neg CTR 0.122 0.004 
 
SALL4 after rescaling (log scale)
0.010
0.100
1.000
10.000
100.000
1 2 3 4 5 6 7 8
SALL4
Sample ID Sample Expression level SD 
1 hAEC T0 0.118 0.132 
2 hAEC P1 0.124 0.003 
3 hAEC P3 0.105 0.034 
4 hAMSC T0 0.118 0.013 
5 hAMSC 1P 0.408 0.025 
6 hAMSC 3P 1.000 0.046 
7 ES 17.564 3.102 
8 Neg CTR 0.010 0.002 
 
C
B
A
 
Figure 27 – Rescaled normalized expression of  A) NANOG, B) SALL4 , and C) SNAI1 in hAECs and hAMSCs at 
different passages. Embryonic Stem cells (ES) were used as positive control. RNA from lymphocytes was used as 
negative control.  
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4.2 Epithelial to mesenchymal transition 
In 3 cases, hAECs underwent epithelial to mesenchymal transition (EMT) acquiring a more spindle-
shaped morphology (Fig. 28A) and expressing typical mesenchymal markers as CD105 and 
S100A4 (Fig. 28B). However, the expression of epithelial markers was maintained (Fig. 28C). 
 
 
              
 
          
CD105
 
Passage 1
Passage 3
Isotypic control  
 
 
Surface antigens 
Flow 
cytometry 
 Intracellular 
antigens IF staining 
EpCAM 0.3  CK7 ++ 
CD166 84  CK18 ++ 
CD49f 7  CK19 ++ 
CD29 98  AFP - 
CD73 97  S100A4 ++ 
CD105 67  
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CD166
Figure 28 - Characterization of hAECs underwent EMT at 3rd split by flow cytometry and immunofluorescence: (A) 
cellular morphology (20x); (B) expression by IF of S100A4 (DAPI blue, 20x); (C) comparison between expression by 
flow cytometry of CD105 at 1st (green) and 3rd split (pink) and (D) expression of CD166 at 1st (green) and 3rd split 
(pink) In gray: isotypic control; (D) membrane antigens expression (left table) and intracytoplasmic antigens (right 
tab). 
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4.3 Cell differentiation ability 
4.3.1 In vitro differentiation into osteocytes and adipocytes 
To determine whether hAECs and hAMSCs could differentiate into adipocytes, cells were allowed 
to grow to 70% confluence prior to induction. Morphological changes as well as formation of lipid 
vacuoles within the cells were noticeable one week post induction and were visualized by Oil-Red-
O staining (Fig. 29B and 29C). Cells maintained in control medium did not show any sign of 
adipogenic differentiation (Fig. 29A).  
To investigate the osteogenic potential of hAECs and hAMSCs, cells were cultured under 
appropriate condition for differentiation. The presence of calcium deposits in induced and control 
cultures was determined by Alizarin Red at 2% in water at pH 4.2 (Fig. 29E and 29F). Cells 
maintained in control media did not show any change in their morphology and no calcium deposit 
(Fig. 29D). 
 
A
B
C
D
E
F
 
Figure 29 – Adipocyte (left column) and osteocyte (right column) differentiation of hAECs and hAMSCs. Phase 
contrast micrograph of hAECs cultured in A) basal medium stained with Oil-red-O and D) hAMSCs cultured in basal 
medium stained with Alizarin Red. Light microscope showed lipid vacuole after adipogenic stimulation of hAEC (B) 
and hAMSCs (C) and calcium deposit after osteogenic strimulation for hAECs (E) and hAMSCs (F). 
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4.3.2 In vitro differentiation into hepatocytes 
To determine whether hAECs and hAMSCs could differentiate into hepatocytes, cells were allowed 
to grow to 8 days prior to induction. After 10 days of induction, the cells were incubated for 2 hours 
with Diethoxy (5,6) chloromethylfluorescein. The generation of fluorescent products was evaluated 
by fluorescence scanning microscopy. Both hAECs and hAMSCs showed few signs of hepatocyte 
differentiation (Fig. 30). Cells maintained in control medium did not show any sign of hepatocyte 
differentiation (Fig. 30A). 
 
 
A C
B D
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 – Hepatocyte differentiation of hAECs and hAMSCs. A) Cells grown in basal 
medium as control; B) hAMSCs , C) and D) hAECs grown in induced medium in the 
presence of Diethoxy (5,6) chloromethylfluorescein. 
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4.4 Differentiation into airway epithelium 
4.4.1 CFTR protein expression by flow cytometry 
hAMSCs stained with CM-DiI (as described in Materials and Methods section) were mixed with 
CFBE41o- cells at different increasing ratios (1:20, 1:15, 1:10 and 1:5) and seeded onto semi-
permeable filters (Transwells). After 7 days of co-culture, different parameters were studied, 
including CFTR expression and ZO-1 localization at the cell junctions.  
In order to analyze the CFTR protein expression in hAMSC-CFBE41o- co-cultures at different 
ratios, a flow cytometric assay was performed on day 7 of co-cultivation. This mixed population 
was analyzed after labelling with CFTR antibody MAB25031 mouse IgG2a in the absence of 
permeabilization followed by incubation with FITC-conjugated secondary antibody. As a 
background control, co-cultures were incubated with secondary antibody only, and the resulting 
fluorescence was subtracted from the analyzed samples incubated both with primary and secondary 
antibodies. As a positive control, CFTR labelling was assessed in normal human airway 
16HBE14o- cells, resulting in 60-70% of positive cells (data not shown). CFBE41o- cells did not 
show any CFTR-specific labelling, consistent with the lack of CFTR transport on the plasma 
membrane which is a characteristic of these cells (Fig. 31). Flow cytometry data showed an increase 
of  both green (given by CFTR) and red  (given by CM-DiI) fluorescence percentage at all hAMSC-
CFBE ratios as compared with CFBE41o- cells, demonstrating that a specific signal due to CFTR 
expression is associated with hAMSCs labelled with the vital dye. In particular, at the ratio of 1:5, 
10.6% of the whole population showed both green and red positive staining, and this value 
decreased by reducing hAMSC number in co-cultures. Interestingly, this value corresponds to 
approximately 50% of the total MSC population (Table 4). The percentage of CFTR-positive 
hAMSCs in the whole hAMSC population increased at lower cell ratios to reach 70-80% of the 
whole hAMSC population (Table 4), probably because a better performance of the antibody on less 
hAMSCs. Overall, these data show that at least 50-80% of hAMSCs has acquired a detectable 
CFTR expression above the CFBE background. 
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Figure 31 - CFTR expression in CM-DiI labelled hAMSCs co-cultured with CFBE41o- cells by cytofluorimetric 
analysis. FL1 indicates green fluorescence (CFTR), while FL2 the red fluorescence (CM-DiI) 
  
 
 
Table 4. Percentages of CFTR+ hAMSCs labelled with CM-DiI in co-cultures with CFBE 41o- 
cells. 
 CM-DiI+/CFTR+ cells 
% of CFTR+ in whole CM-
DiI+ population 
CFBE 1.2 % 0 % 
hAMSC-CFBE 1:5 10.6 % 53 % 
hAMSC-CFBE 1:10 6.9 % 69 % 
hAMSC-CFBE 1:15 5.3 % 79 % 
hAMSC-CFBE 1:20 3.4 % 68 % 
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4.4.2 CFTR expression and localization by confocal microscopy 
To confirm cytofluorimetric data and to analyze CFTR expression in cell compartments, hAMSCs-
CFBE co-cultures were assayed by means of confocal microscopy. In previously published work 
(Guerra et al, 2005), it has been demonstrated that CFTR protein is expressed on the apical side of 
16HBE14o- cells, while CFBE 41o- cells display only intracellular staining. After 7 days of co-
cultivation, CFTR expression and localization was evaluated by epifluorescence with a protocol 
which allows detecting only surface and not intracellular CFTR (see Materials and Methods 
section), followed by confocal microscopy analysis. As can be seen in Figure 32, CFTR was highly 
expressed on the apical membrane of some hAMSCs since red labelled cells showed a green 
staining at membrane level, whereas CFBE41o- monolayers in absence of hAMSCs showed a 
background signal for CFTR expression, consistent with the lack of CFTR transport to the apical 
membrane in CF cells. These data confirm cytofluorimetric analysis as to the surface expression of 
CFTR in labelled hAMSCs. 
 
 
Figure 32 - CFTR immunodetection by confocal analysis. Confocal scans are shown in the horizontal cross-section (xy) 
plane and  vertical cross-section (xz) plane. The white arrows point to CM-DiI labelled hAMSCs expressing CFTR on 
their membrane (green signal). 
 
RESULTS: Differentiation into airway epithelium 
 
 
75 
4.4.3 ZO-1 expression and organisation  
hAMSC-CFBE41o- co-cultures at different ratios were examined by confocal analysis for the 
expression of structural markers involved in tight junction (TJ) organization, in particular we 
focused on ZO-1 protein. In CFBE41o- cells cultured without hAMSCs, the immunostaining 
showed that ZO-1 was not properly localized at TJ level as compared with wild-type 16HBE14o- 
cells (Fig. 33). In particular, in 16HBE14o- cells, ZO-1 staining produced a typical chicken wire-
like pattern, indicating the presence of intact TJs. Moreover, we observed that co-culturing the 
CFBE41o- with hAMSCs induced a small re-organisation of ZO-1 at the level of TJs at the highest 
ratio. In particular, in presence of hAMSCs the junctional ZO-1 localization is slightly more 
distinctive at 1:5 (Fig. 33) and 1:10 (not shown) ratios, but still in part disorganized, while it 
resulted not properly organized at 1:15 and 1:20 (Fig. 33) ratios. However, it can be seen that ZO-1 
expression increased in all co-culturing conditions, indicating that the presence of hAMSCs has 
induced a higher expression and a better reorganization of ZO-1 at cell borders. 
 
 
Figure 33- ZO-1 immunodetection by confocal analysis. Confocal scans are shown in the horizontal cross-section (xy) 
plane and  vertical cross-section (xz) plane. In the lower left panel, the white arrow points to a CM-DiI labelled 
hAMSC. Please note that ZO-1 expression (green signal between the cells) is higher and more precisely delineating cell 
borders in the 1:5 ratio than in the 1:20 ratio. 
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4.4.4 Transepithelial resistance measurement 
To evaluate the polarization of hAECs and hAMSCs, transepithelial resistance (TER) was measured 
at different days of culture, both for isolated cultivation (Fig. 34) and for hAMSC-CFBE41o- co-
cultures at different ratios (Fig. 35). First, we measured TER in polarized non-CF 16HBE14o- 
control cells, and on CFBE41o- cells, hAMSCs, and hAECs alone. Non-CF 16HBE14o-  showed a 
higher TER than CFBE41o- cells or hAMSCs and hAECs. Both hAECs and hAMSCs showed a 
slight increase in TER during culture, even if the value remained lower than that of 16HBE14o- 
(Fig. 34). 
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Figure 34 – TER in  16HBE14o-, CFBE41o-, in hAECs and in hAMSCs cells. 
 
 
 
 
Then we measured TER on co-cultures of hAMSC-CFBE41o- cells at different ratios. CFBE41o- 
cells showed a lower TER as compared with 16HBE14o-, consistent with a non polarization of CF 
cells. Starting from day 6 of culture, TER slightly increased when CFBE41o- were co-cultured with 
hAMSCs respect to CFBE41o- cells alone, above all with higher hAMSC-CFBE ratios of 1:5. 
These results could indicate a partial correction of the CF phenotype, as evaluated by TER, in the 
presence of hAMSCs at least in higher ratios (Fig. 35). 
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Figure 35 - TER in  CFBE41o-, and in co-cultures of hAMSC-CFBE41o- cells. 
 
 
 
4.4.5 Fluid Absorption  
To evaluate the effect on the physiology of CFBE41o- cells by culturing them with hAMSCs at 
different ratios, we measured fluid absorption. First, we measured fluid transport in polarized non-
CF 16HBE14o- control cells, incubated in the absence or in the presence of 10 mM or 100 mM 
amiloride for 24 h. Amiloride is a known inhibitor of ENaC (Caci et al, 2009). As shown in Figure 
36, addition of amiloride reduced with a dose dependency ENaC-dependent fluid absorption from 
the apical side of the epithelium up to 80%. Then we measured fluid absorption on CFBE41o- cells 
alone, or on co-cultures of hAMSC-CFBE41o- cells. CFBE41o- cells showed a higher fluid 
absorption as compared with 16HBE14o-, consistent with a higher ENaC activity. Fluid absorption 
slightly decreased when CFBE41o- were co-cultured with hAMSCs respect to CFBE41o- cells 
alone, above all with higher hAMSC-CFBE ratios of 1:5 and 1:10. In these experiments we used 
amiloride at 100 mM, which was the most effective concentration that inhibited fluid absorption in 
16HBE control cells. Amiloride treatment strongly decreased fluid absorption at higher ratios 
tested. These results strongly indicate a partial correction of the CF phenotype, as evaluated by fluid 
absorption, in the presence of hAMSCs. 
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Figure 36- Fluid absorption in 16HBE14o-, CFBE41o-, and in co-cultures of hAMSC-CFBE41o- cells. 
 
  
 
4.4.6 RT-PCR  
To demonstrate that hAECs and hAMSCs can express ENaC subunits, RT-PCR analysis was 
performed. hAMSCs expressed α and β subunits of EnaC, but not γ subunit (Fig. 37).  
 
 
 
Figure 37 - RT-PCR for α, β, and γ ENaC subunits on hAECs and hAMSCs. M molecular weight markers; Ctr+ 
positive control (H441 treated with dexamethasone). 
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CFTR was detected in hAECs and in hAMSCs only after nested PCR. Moreover, while hAEC 
expressed CFTR at different passages, CFTR expression in hAMSC decreased dramatically during 
culture (Fig. 38). 
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Figure 38 – RT-PCR for CFTR on hAECs and hAMSCs at different passages. M molecular weight markers; Ctr+ 
positive control; Ctr- negative control. 
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5. DISCUSSION 
Cystic fibrosis (CF) is the most frequent severe autosomal recessive disorder in the European 
population. There are a number of reasons why CF should be an ideal disease for the application of 
gene therapy (Conese and Rejman, 2006). First of all, it is caused by a single-gene defect. Secondly, 
the main pathology is in the lung, an organ which is relatively easily accessible for treatment. In 
addition it offers a therapeutic window for treatment since CF patients demonstrate an almost 
normal phenotype at birth. Finally, it has been suggested that restoration of CFTR function to a 
level of only 5–10% of normal will be sufficient to adequately reverse the chloride transport 
dysfunction (Johnson et al, 1992; Ramalho et al, 2002) and give complete recovery of the intestinal 
disease in CF mice (Dorin et al, 1996). However, despite these encouraging features, clinical trials 
of gene therapy in CF patients have only resulted in inconsistent and low levels of vector-specific 
CFTR expression and at best minor functional changes towards normality (Davies et al, 2001). 
This has led to a search for alternative approaches including the use of stem cell populations. CF is 
a potential model disease for stem cell therapy because of the persistent lung inflammation that 
leads to damage and remodeling, and can promote engraftment of stem cells (Piro et al, 2008).  
A developing potential therapeutic approach for CF and other lung diseases has been stimulated by 
recent reports demonstrating that several cell populations derived from adult bone marrow, from 
amniotic fluid or from umbilical cord blood, including stromal derived mesenchymal stem cells 
(MSCs), endothelial progenitor cells, and circulating fibrocytes, can localize to a variety of organs 
and acquire phenotypic and functional markers of mature organ-specific cells (Korbling and Estrov, 
2003; Prockop, 2003; Herzog et al, 2003; Weiss et al, 2006; Sueblinvong et al, 2008; Carraro et al, 
2008). 
The in vivo efficiency of bone marrow stem cells to differentiate in airway epithelium is very low 
(0.01-0.025%) (Piro et al, 2008), as demonstrated by different studies in mice (Loi et al, 2006; 
Bruscia et al, 2006). Importantly, it has been reported that circulating bone marrow-derived stem 
cells preferentially home to the damaged respiratory epithelium undergoing regeneration (Theise et 
al, 2002; Kotton et al, 2001). In order to facilitate cell homing and epithelium differentiation of 
these cells, pulmonary damage can be induced by chemical or physical agents, as bleomycin or X-
ray radiation.  
Recent studies demonstrate that with 0.1% of donor cells that became respiratory host cells a partial 
correction of the electrophysiological defect has been obtained (Bruscia et al, 2006). On the 
contrary, other studies demonstrate that a higher percentage (6-20%) of corrected cells is needed to 
revert the defect (Farmen et al, 2005).  
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The results published by Wang (Wang et al, 2005) and Loi (Loi et al, 2006) strongly suggest that 
the population of bone marrow cells relevant for repopulating the lung epithelium may be found in 
the plastic adherent stromal cell compartment. Yet, mesenchymal stem cells are not without 
drawbacks, e.g. they are limited in numbers and lack well-defined markers required for their 
purification (Herzog et al, 2003). One approach to overcome these limitations is to consider 
alternative sources of stem cells capable of repopulating damaged respiratory epithelium.  
In the present study, we propose human placenta as an ethical source of stem cells for CF therapy.  
It is well established that human placenta may represent a reserve of progenitor/stem cells. As a 
potential source of cells for application in regenerative medicine, the placenta has the advantage of 
being a natural by-product of birth which is often simply discarded, while harvest of term amniotic 
membrane does not pose any risk to the mother or newborn. Amniotic epithelial cells (hAECs) and 
amniotic mesenchimal stromal cells (hAMSCs) are known to have unique characteristics, such as 
low level expression of major hystocompatibility complex antigens, and a less restricted 
differentiation potential (Miki and Strom, 2006). The availability of hAECs and hAMSCs and the 
lack of ethical concerns for this source of stem cells are considered advantageous for their 
widespread use and acceptance.  
Isolated cells readily attached to plastic dishes and they can be kept in culture in a simple medium 
supplemented with EGF. hAECs displayed typical cuboidal epithelial morphology and can be kept 
until 2-6 passages before proliferation ceased. hAECs presented different surface markers, 
suggesting some heterogeneity of phenotype (Parolini et al, 2008). Immediately after isolation, 
hAECs appear to express low molecular weight cytokeratin, EpCAM, integrin α6 (CD49f), integrin 
β1 (CD29), E-cadherin, zonula adherens-1 (ZO-1). The expression of CD90 (Thy-1) antigens 
appeared to be stable during culture. hAECs expressed not only epidermal markers and general 
epithelial markers, but also expressed vimentin. We also demonstrated that mRNA expression of 
SNAI1, a transcriptional repressor which downregulates the expression of ectodermal genes within 
the mesoderm, increased in hAEC during passages. These facts suggested that the epithelial-
mesenchymal transition (EMT) may occur in the amniotic membrane (Parolini et al, 2008). Indeed, 
in three cases, hAECs underwent EMT, acquiring a more spindle-shaped morphology and 
expressing typical mesenchymal markers. 
hAMSC displayed a fibroblastic morphology and can be kept until passages 5-10 in culture. 
hAMSCs presented surface markers associated with mesenchymal cells from bone marrow, as 
CD105, CD73, and CD90, and mesenchymal specific marker as vimentin. They also displayed 
positivity for CK18, and CD29. This hybrid phenotype of hAMSCs  is interpreted as a sign of 
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multipotentiality, and suggests that the amnion derived cells had not completely differentiated into 
epithelial or mesenchymal cells (Parolini et al, 2008). 
Cytogenetic analyses of hAECs and hAMSCs revealed that these cells are of fetal origin and 
maintain normal karyotypes at different passages. 
As shown here, the amniotic cells derived from term placenta seem to remain somewhat “plastic” in 
their differentiation options and maintain the capability to differentiate and contribute to cells from  
different germ layers. In particular, we demonstrated that hAECs and hAMSCs differentiate into 
mesodermal (adipocyte and osteocyte) and endodermal (hepatocyte) lineages. 
Because amniotic cells can differentiate to different types, we examined them with antibodies 
directed against well-known surface markers characteristic of ES cells. Like ESCs, amniotic cells 
express SSEA-4, although the relative proportion of SSEA-positive cells in initial isolates of 
amniotic cells is lower than that observed with ESCs. We speculate that more differentiated cells in 
the amnion may lose stem cell surface markers. In addition to characteristic stem cell surface 
markers, amniotic cells show mRNA expression of Nanog, a transcription factor with an expression 
pattern previously reported to be restricted to pluripotent stem cells (In’t Anker et al, 2003; Prusa et 
al, 2003), and Sall4,  a member of spalt-like protein family, which seems to interact with Nanog in 
vitro and exist as a complex with Nanog (Wu et al, 2006). 
Both genes were readily detected in hAECs and hAMSCs cells at the time of isolation, and during 
culture, even if their expression seems to decrease with time, probably due to the fact that more 
differentiated cells may lose pluripotency markers during culture passages. Based on the expression 
of Oct-4, SSEA-4, Nanog and Sall4, amniotic membrane may contain around 10% stem cell 
marker-positive cells. These findings are consistent with those reported by a recent paper (Miki et 
al, 2009), which suggested that in terms of stem cell characteristics and differentiation potential, 
amniotic cells may be somewhere between pluripotent ESC clusters and multipotent neural 
stem/progenitor cell spheres.  
Furthermore, for the first time our results provide evidence that hAECs and hAMSCs can be 
induced in vitro to express markers of airway epithelial phenotype, including ZO-1 and CFTR, and 
so have the potential to differentiate into airway epithelial cells.  
To evaluate this, we performed a dose-dependent experiment: hAMSCs stained with CM-DiI were 
mixed with CFBE41o- cells at different increasing ratios (1:20, 1:15, 1:10 and 1:5) and seeded onto 
semi-permeable filters (Transwells). CFBE41o- cells did not show any CFTR-specific labelling, 
consistent with the lack of CFTR transport on the plasma membrane which is a characteristic of 
these cells. Flow cytometry data showed that CFTR and CM-DiI fluorescence increase in hAMSCs-
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CFBE co-cultures, demonstrating that a specific signal due to CFTR expression is associated with 
hAMSCs labelled with the vital dye. In particular, at the ratio of 1:5, 10.6% of the whole population 
showed both CFTR and CM-DiI positive staining, and this value decreased by reducing hAMSC 
number in co-cultures. Overall, our data showed that at least 50-80% of hAMSCs has acquired a 
detectable CFTR expression above the CFBE background. 
To confirm cytofluorimetric data and to analyze CFTR expression in cell compartments, hAMSCs-
CFBE co-cultures were assayed by means of confocal microscopy. CFTR was highly expressed on 
the apical membrane of some hAMSCs, whereas CFBE41o- monolayers in absence of hAMSCs 
showed a background signal for CFTR expression, consistent with the lack of CFTR transport to the 
apical membrane in CF cells. 
CFTR expression was evaluated by PCR in hAECs and in hAMSCs. While hAEC expressed CFTR 
at different passages, CFTR expression in hAMSC is low, and decreased dramatically during 
culture. Overall, the data suggest that low CFTR expression in hAMSCs can be increased by co-
cultivation with CFBE, probably due to paracrine or autocrine signaling. 
Afterwards, we examined hAMSC-CFBE41o- co-cultures at different ratios by confocal analysis 
for the expression of structural markers involved in tight junction (TJ) organization, in particular 
ZO-1 protein. In CFBE41o- cells cultured without hAMSCs, ZO-1 was not properly localized at TJ 
level as compared with wild-type 16HBE14o- cells, where it produced a typical chicken wire-like 
pattern, indicating the presence of intact TJs. Moreover, we observed that co-culturing the 
CFBE41o- with hAMSCs induced a small re-organisation of ZO-1 at the level of TJs at the highest 
ratio, and not at the lowest ratios. However, it can be seen that ZO-1 expression increased in all co-
culturing conditions, indicating that the presence of hAMSCs has induced a higher expression and a 
better reorganization of ZO-1 at cell borders. 
We then demonstrated that hAECs and hAMSCs can polarize when grown onto semi-permeable 
filters at the air-liquid interface. In order to evaluate the polarization, we measured transepithelial 
resistance (TER) at different days of culture and we observed that amniotic cells presented a slight 
increase in TER during culture, suggesting the establishment of tight junctions across the 
monolayer, even if the value remained lower than that of non-CF 16HBE14o- cells. 
After that, we measured TER on co-cultures of hAMSC-CFBE41o- cells at different ratios. 
CFBE41o- cells showed a lower TER as compared with 16HBE14o-, consistent with a non 
polarization of CF cells. Starting from day 6 of culture, TER slightly increased when CFBE41o- 
were co-cultured with hAMSCs respect to CFBE41o- cells alone, above all with higher hAMSC-
CFBE ratios. 
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Overall, these results could indicate a partial correction of the CF phenotype in the presence of 
hAMSCs at least in higher ratios, suggesting a directly proportional effect of the percentage of 
hAMSCs in co-cultivation. Still, it seems that only a subpopulation of hAMSCs (50-80%) are 
capable of contributing to the establishment of respiratory epithelial cell monolayer in this system.  
Recent reports have suggested two possible mechanisms to explain the plasticity of mesenchymal 
stem cells: transdifferentiation and cell fusion (Spees et al, 2003). A previous paper suggested that 
cell fusion is a rare event in the air-liquid interface system and, even if mesenchymal stem cells 
undergo cell fusion with epithelia, they still can be therapeutically beneficial if the corrected CFTR 
gene is expressed (Wang et al, 2005). 
To evaluate the effect on the physiology of CFBE41o- cells by culturing them with hAMSCs at 
different ratios, we measured fluid absorption.  
The volume of the surface fluid covering the airways is maintained through a fine balance between 
ion and water secretion and absorption. This is obtained by exerting a tight control of the activity of 
ion channels and transporters localized on the apical and basolateral membranes of epithelial cells. 
In particular, Na
+
 absorption through the epithelial Na
+
 channel (ENaC), localized in the apical 
membrane, and the Na/K-ATPase, in the basolateral membrane, is in equilibrium with Cl
-
 secretion 
through the CFTR and other Cl
-
 channels in the apical membrane, and the Na-K-Cl (NKCC) 
cotransporter in the basolateral membrane (Boucher, 1994). An appropriate volume of periciliary 
fluid is essential not only to allow cilia beating, but also to maintain the hydration and therefore the 
proper visco-elastic characteristics of mucus. The correct performance of these two processes, 
absorption and secretion, ensures an effective mucociliary clearance. In CF, the equilibrium 
between absorption and secretion is disrupted by mutations in the CFTR Cl
-
 channel. As a 
consequence, Cl
-
 secretion is strongly reduced and Na
+
 absorption becomes predominant. 
Accordingly, airways of patients with CF are dehydrated, obstructed by thick mucus, inflamed, and 
frequently infected (Matsui et al, 1998). 
The negative effects of the disequilibrium between Na+ absorption and Cl- secretion has been also 
demonstrated by the production of a transgenic mouse that hyperexpresses the β subunit of the 
ENaC (Mall et al, 2004). In this mouse, the increased Na
+
 and water absorption produces a CF-like 
lung disease, characterized by surface liquid depletion, increased mucus concentration and stasis, 
inflammation, and poor bacterial clearance. It has been suggested that down-regulation of ENaC 
may help to restore airway hydration and mucus clearance, and to reverse, at least partially, the 
airway phenotype in patients with CF. Amiloride is a known inhibitor of ENaC (Caci et al, 2009). 
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The reduction of ENaC activity does have functional consequences on the airways, as demonstrated 
by the fluid measurements.  
First, we measured fluid transport in polarized non-CF 16HBE14o- control cells, incubated in the 
absence or in the presence of 10 mM or 100 mM amiloride for 24 h. Addition of amiloride reduced 
with a dose dependency ENaC-dependent fluid absorption from the apical side of the epithelium up 
to 80%. Then we measured fluid absorption on CFBE41o- cells alone, or on co-cultures of hAMSC-
CFBE41o- cells. CFBE41o- cells showed a higher fluid absorption as compared with 16HBE14o-, 
consistent with a higher ENaC activity. Fluid absorption slightly decreased when CFBE41o- were 
co-cultured with hAMSCs respect to CFBE41o- cells alone, above all with higher hAMSC-CFBE 
ratios. In these experiments we used amiloride at 100 mM, which was the most effective 
concentration that inhibited fluid absorption in 16HBE control cells. Amiloride treatment strongly 
decreased fluid absorption at higher ratios tested.  
To demonstrate that hAECs and hAMSCs can express ENaC subunits, RT-PCR analysis was 
performed. hAMSCs expressed α and β subunits of ENaC, but not γ subunit. The relative 
expression found here, characterized by a preponderance of α subunit followed by β and with low 
levels of γ, is similar to that described previously in human airways (Burch et al, 1995). 
Explanations for the unbalanced expression could be that excess in α subunit, the only subunit able 
to form an active channel, might assure a certain level of ENaC function. In contrast, the low 
expression levels of β and γ could suggest that they are more prone to modulation by external 
factors, such as hormones, cytokines, and so on (Caci et al, 2009). 
Such experiments show a reduction in fluid absorption through the airway epithelium monolayer, 
suggesting that the periciliary fluid volume would increase and, as a consequence, there would be 
an improvement in mucociliary clearance. 
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6. CONCLUSION AND FUTURE PERSPECTIVES 
The opportunity of having a fetal tissue rich in cells with stem cell characteristics and the capacity 
to differentiate towards the three germinal cells lines, with low immunogenicity, non tumorigenicity 
and non ethical barriers, make the amniotic membrane an alternative source of stem cells 
particularly interesting in the context of cell based therapy applications such as transplantation and 
regenerative medicine.  
We have identified cells in the human amniotic membrane with characteristics of airway epithelial 
progenitors expressing CFTR and ZO-1, particularly when co-cultivated under air-liquid interface 
cultures with CF human epithelial bronchial cells. Amniotic cells has stem cell characteristics 
including self-renewal and multi-epithelial lineage differentiation potential.  
Overall, our data show that these cells may contribute to partial correction of the CF phenotype and 
are very likely an ideal candidate for cell-based therapy for CF. 
Whether the beneficial effects of placenta-derived cells are due to differentiation of the transplanted 
cells themselves or to paracrine actions on the surrounding host tissue in order to reduce 
inflammation and promote regeneration remains to be fully elucidated, although current evidence 
seems to lend greater support to the latter of these hypotheses. In any case, the promising data 
obtained to date constitute compelling evidence regarding the potential utility of these cells for 
clinical application.  
Surely the true potential of amniotic cells for CF therapy requires testing in in vivo models. Future 
studies aiming at evaluating the in vivo ability of engraftment and differentiation of amniotic cells 
in NOD-SCID mice are needed. The NOD-SCID mouse represents a pre-clinic model used for the 
evaluation of the therapeutic effect of human stem cells. Despite rare engraftment of airway 
epithelium, there are an increasing number of studies demonstrating a functional role of stem cells 
in the mitigation of lung injury. After the optimization of the transplant conditions, the ability of 
reverting the electrophysiological defect of the cells should be evaluated in a model of CF mouse.  
The use of a in-vivo model will help in finding a strategy of cell therapy for the cure of respiratory 
disease of CF, directly transferable to CF patients. 
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Consenso informato alla conservazione di campioni biologici in vista di 
studi futuri 
 
INFORMAZIONE  
 
Gentile Sig.ra, 
La informiamo che, se presta il Suo consenso, dopo il parto saranno prelevati alcuni 
campioni della placenta, tessuto generalmente eliminato dopo il parto, che verranno 
processati/conservati presso l’U.O. 517 e/o presso la Biobanca Italiana, una struttura 
pubblica per la raccolta di campioni biologici (ad esempio, sangue, cellule, tessuti) con 
sede presso la Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina 
Elena di Milano.  
 
Modalità di prelievo dei campioni 
Tali campioni saranno ricavati dal materiale biologico che residua dopo il parto.  
Tale prelievo non comporterà alcun rischio per la Sua salute o quella del neonato. 
 
Finalità e natura degli studi 
I campioni prelevati potranno essere utilizzati, anche in futuro, per compiere indagini 
di carattere anatomopatologico, molecolare o genetico. Tali studi saranno finalizzati ad 
un miglioramento delle metodiche di caratterizzazione e utilizzo delle cellule 
staminali. 
                      
Sviluppi correlati agli studi 
I risultati acquisiti dal compimento di tali indagini potranno essere utilizzati, in forma 
anonima, in pubblicazioni scientifiche. Inoltre essi potranno contribuire allo sviluppo 
di nuove modalità terapeutiche. Nel rispetto delle normative vigenti i proventi ricavati 
dallo sviluppo di tali prodotti potranno essere impiegati ad esclusivo beneficio della 
collettività.  
 
Tutela della riservatezza 
I Suoi campioni e i dati personali e clinici ad essi associati verranno trattati dai 
ricercatori e dal personale incaricato in modo da garantire il rispetto della Sua 
riservatezza e potranno essere condivisi, sempre in forma anonima, con altri 
ricercatori. 
 
Informazioni sui risultati degli studi e su eventuali indagini future 
Se lo desidera, potrà ricevere informazioni sull’andamento degli studi che verranno 
compiuti usando i Suoi campioni e sui risultati ottenuti sino a quel momento. 
In futuro i Suoi campioni potranno essere utilizzati per proseguire tali studi o per 
intraprendere nuove indagini ad essi correlate, senza necessità di chiedere un nuovo 
consenso.  
 
U.O.C. CENTRO FIBROSI CISTICA  
DIRETTORE PROF. CARLA COLOMBO 
VIA COMMENDA 9, 20122 MILANO 
TEL 0255032456 FAX 0255032814 
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Revoca del consenso 
In qualunque momento e per qualunque motivazione potrà revocare il Suo consenso 
alla conservazione dei campioni e/o al loro utilizzo e potrà chiedere che i Suoi campioni 
e i dati clinici e personali ad essi associati siano eliminati. Tali scelte non avranno 
alcun effetto negativo sulla Sua assistenza medica. Esse, tuttavia, potranno impedire 
la continuazione degli studi intrapresi o l’avvio di nuovi studi correlati. 
 
CONSENSO 
 
In base alle informazioni che ho ricevuto e avendo avuto la possibilità di chiedere 
spiegazioni,   
 
ACCONSENTO che: 
1. I campioni biologici prelevati siano conservati nelle sedi segnalate.  
□ SI     □ NO 
2. I campioni biologici e i dati personali e clinici ad essi associati siano utilizzati per 
compiere in futuro indagini finalizzate al miglioramento di metodiche analitiche e 
terapeutiche 
□ SI     □ NO 
3. I campioni e i dati personali e clinici ad essi associati siano inoltre utilizzati per 
proseguire tali studi e/o compiere nuove indagini ad essi correlate, senza necessità 
di prestare un nuovo consenso 
□ SI     □ NO 
 
4. I campioni biologici e i dati personali e clinici ad essi associati vengano utilizzati in 
forma anonima dai ricercatori e dal personale incaricato e siano condivisi, sempre 
in forma anonima, con altri ricercatori  
□ SI     □ NO 
5. I risultati acquisiti dal compimento di tali indagini possano essere utilizzati in 
forma anonima in pubblicazioni scientifiche e/o possano contribuire allo sviluppo di 
nuove modalità terapeutiche derivanti da tali indagini  
□ SI     □ NO 
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DICHIARO di: 
 
6. aver ricevuto informazioni sulla possibilità di revocare il consenso alla 
conservazione e/o utilizzo dei miei campioni e dei dati ad essi associati in 
qualunque momento e per qualunque motivazione  
 □ SI     □ NO 
7. voler ricevere informazioni sui risultati confermati dagli esami analitici compiuti 
durante lo svolgimento degli studi e su eventuali nuovi risultati e/o possibilità 
diagnostiche/terapeutiche derivanti da tali indagini  
□ SI     □ NO 
 
 
 
Data__________________ 
 
 Il paziente_____________________________            Firma_______________________ 
 
 Il presente consenso è stato raccolto da: 
 
 Dr ____________________________________ Firma___________________________ 
  
 Qualifica ______________________________ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RINGRAZIAMENTI 
112 
 
RINGRAZIAMENTI 
 
Ringrazio la Prof.ssa Carla Colombo per avermi offerto questa opportunità e per avermi 
seguito in questi anni di dottorato. 
 
Ringrazio il Prof. Massimo Conese per l’ideazione del progetto e per il suo supporto tecnico e 
critico a distanza. Un grazie di cuore va al Dott. Stefano Castellani e ad Annalucia per il grande 
apporto offerto a questo lavoro. 
 
Ringrazio la Dr.ssa Laura Porretti per avermi ospitato nel laboratorio di Citometria e Silvia, 
Francesca, Federico e Alessandra per la loro disponibilità, per il loro prezioso aiuto negli 
esperimenti e per l’enorme sostegno offertomi nell’affrontare le problematiche di questo progetto. 
 
Ringrazio tutti i colleghi del Laboratorio di Genetica Molecolare ed in particolare la Dr.ssa 
Manuela Seia per avermi introdotto al mondo della Fibrosi Cistica, Lucy per avermi sempre 
consigliato ed aiutato in ogni mio problema, Damiana per la sua collaborazione, Patrizia e Gigi 
per il loro supporto  morale. 
 
Ringrazio  la Dr.ssa Marina Di Segni e Gabriele per il loro contributo. 
 
Un ringraziamento speciale a Maurizio, che resterà per sempre nel mio cuore un esempio di 
sincerità, forza e sensibilità.   
 
Grazie ancora a Papà e Michela per avermi sempre sostenuto.  
 
Grazie a Mamma per avermi insegnato ad affrontare le sfide della vita e a gioire delle piccole 
conquiste e per essere sempre presente, ovunque lei sia. 
 
Un grazie speciale infine al mio immenso amore Massimo, per aver avuto la pazienza di 
sopportarmi e la forza di affrontare insieme a me ogni ostacolo, per aver condiviso con me le gioie 
e i dolori degli ultimi anni, per riuscire sempre a farmi sorridere, e per regalarmi ogni giorno un 
motivo per essere felice. 
 
 
Valentina 
 
